Volcano (VOLC) 10-Q 7 Nov 13 2013 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2013	Oct. 31, 2013
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Entity Registrant Name	'Volcano Corp	'
Entity Central Index Key	'0001354217	'
Trading Symbol	'volc	'
Entity Filer Category	'Large Accelerated Filer	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	54,887,281

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$211,406	$330,635
Short-term available-for-sale investments	188,778	140,960
Accounts receivable, net	76,297	76,348
Inventories	66,967	52,811
Prepaid expenses and other current assets	33,260	21,773
Total current assets	576,708	622,527
Long-term available-for-sale investments	89,210	44,385
Property and equipment, net	119,965	104,385
Intangible assets, net	60,631	50,657
Goodwill	53,082	51,577
Other non-current assets	28,104	28,813
Total assets	927,700	902,344
Current liabilities:	'	'
Accounts payable	15,418	16,284
Accrued compensation	23,615	23,227
Accrued expenses and other current liabilities	24,473	23,529
Deferred revenues	9,453	9,789
Contingent consideration	2,911	2,908
Total current liabilities	75,870	75,737
Convertible senior notes	396,211	382,300
Other long-term debt	1,232	1,119
Deferred revenues	4,435	4,661
Contingent consideration, non-current portion	29,657	27,323
Other non-current liabilities	7,009	2,859
Total liabilities	514,414	493,999
Commitments and contingencies (Note 4)	'	'
Stockholders’ equity:	'	'
Preferred stock, par value of $0.001; 10,000 shares authorized; no shares issued and outstanding at September 30, 2013 and December 31, 2012	0	0
Common stock, par value of $0.001; 250,000 shares authorized at September 30, 2013 and December 31, 2012; 54,815 and 53,944 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively	55	54
Additional paid-in capital	512,112	494,276
Accumulated other comprehensive loss	-2,974	-4,083
Accumulated deficit	-95,907	-81,902
Total stockholders’ equity	413,286	408,345
Total liabilities and stockholders’ equity	$927,700	$902,344

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value (dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (dollars per share)	$0.00	$0.00
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	54,815,000	53,944,000
Common stock, shares outstanding	54,815,000	53,944,000

Consolidated_Statements_Of_Ope

Consolidated Statements Of Operations (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Statement [Abstract]	'	'	'	'
Revenues	$95,809	$93,656	$290,384	$279,389
Cost of revenues, excluding amortization of intangibles	33,458	33,248	102,624	94,797
Gross profit	62,351	60,408	187,760	184,592
Operating expenses:	'	'	'	'
Selling, general and administrative	45,479	40,699	134,784	127,035
Research and development	16,609	13,032	50,214	40,560
Amortization of intangibles	834	710	2,488	2,470
Acquisition-related items	1,253	0	3,742	0
Restructuring charges	4,616	0	4,874	0
Total operating expenses	68,791	54,441	196,102	170,065
Operating (loss) income	-6,440	5,967	-8,342	14,527
Interest income	327	223	970	656
Interest expense	-6,756	-1,844	-19,908	-4,993
Exchange rate gain (loss)	54	-218	-1,025	-319
Other, net	-33	-23	4,144	-31
(Loss) income before income tax	-12,848	4,105	-24,161	9,840
Income tax (benefit) expense	-4,392	2,130	-10,156	4,295
Net (loss) income	($8,456)	$1,975	($14,005)	$5,545
Net (loss) income per share:	'	'	'	'
Basic (dollars per share)	($0.15)	$0.04	($0.26)	$0.10
Diluted (dollars per share)	($0.15)	$0.04	($0.26)	$0.10
Shares used in calculating net (loss) income per share:	'	'	'	'
Basic (shares)	54,652	53,659	54,466	53,309
Diluted (shares)	54,652	55,265	54,466	55,097

Consolidated_Statements_Of_Com

Consolidated Statements Of Comprehensive Income (Loss) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net (loss) income	($8,456)	$1,975	($14,005)	$5,545
Other comprehensive income	'	'	'	'
Foreign currency translation adjustments	1,522	51	1,527	546
Changes in unrealized gain (loss) on available-for-sale investments, net of tax	'	'	'	'
Changes in unrealized gain (loss) on available-for-sale investments, net of tax	190	100	-4	89
Changes in unrealized losses on foreign currency forward exchange contracts, net of tax	'	'	'	'
Changes in unrealized losses on foreign currency forward exchange contracts, net of tax	-422	0	-414	0
Other comprehensive income	1,290	151	1,109	635
Comprehensive (loss) income	($7,166)	$2,126	($12,896)	$6,180

Consolidated_Statements_Of_Sto

Consolidated Statements Of Stockholders' Equity (USD $)	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
In Thousands, unless otherwise specified
Beginning Balance at Dec. 31, 2012	$408,345	$54	$494,276	($4,083)	($81,902)
Beginning Balance (shares) at Dec. 31, 2012	'	53,944	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Issuance of common stock under equity compensation plans	5,779	1	5,778	'	'
Issuance of common stock under equity compensation plans (shares)	'	871	'	'	'
Employee stock-based compensation cost	12,058	'	12,058	'	'
Net loss	-14,005	'	'	'	-14,005
Other comprehensive loss	1,109	'	'	1,109	'
Ending Balance at Sep. 30, 2013	$413,286	$55	$512,112	($2,974)	($95,907)
Ending Balance (shares) at Sep. 30, 2013	'	54,815	'	'	'

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Operating activities	'	'
Net (loss) income	($14,005)	$5,545
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:	'	'
Depreciation and amortization	18,677	17,448
Amortization (accretion) of investment premium (discount), net	2,305	2,023
Accretion of debt discount on convertible senior notes and other long term liabilities	14,148	3,700
Accretion of contingent consideration	2,537	0
Non-cash stock compensation expense	12,098	11,428
Asset impairment related to restructuring	4,616	0
Gain on sale of other long-term investment	-4,153	0
Effect of exchange rate changes and others	10,797	2,502
Changes in operating assets and liabilities, net of acquisitions:	'	'
Accounts receivable	-3,249	-2,119
Inventories	-15,195	-7,467
Prepaid expenses and other assets	-16,834	-1,847
Accounts payable	-2,599	-521
Accrued compensation	-535	-1,573
Accrued expenses and other liabilities	983	6,077
Deferred revenues	-550	2,088
Net cash provided by operating activities	9,041	37,284
Investing activities	'	'
Purchase of short-term and long-term available-for-sale securities	-342,715	-237,669
Sale or maturity of short-term and long-term available-for-sale securities	247,790	188,556
Cash paid related to acquisitions, net of cash acquired	-15,000	0
Capital expenditures	-26,533	-36,589
Cash paid for other intangible assets and investments	-2,377	-3,107
Proceeds from sale of long-term investments	5,654	0
Proceeds from foreign currency exchange contracts	0	1,187
Payment for foreign currency exchange contracts	0	-215
Net cash used in investing activities	-133,181	-87,837
Financing activities	'	'
Repayment of capital lease liability	-22	-68
Proceeds from sale of common stock under employee stock purchase plan	3,576	3,880
Proceeds from exercise of common stock options	2,203	8,408
Net cash provided by financing activities	5,757	12,220
Effect of exchange rate changes on cash and cash equivalents	-846	24
Net decrease in cash and cash equivalents	-119,229	-38,309
Cash and cash equivalents, beginning of period	330,635	107,016
Cash and cash equivalents, end of period	211,406	68,707
Supplemental disclosures of cash flow information:	'	'
Cash paid for interest	4,542	3,326
Cash paid for income taxes	$3,103	$2,337

Summary_Of_Significant_Account

Summary Of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Summary Of Significant Accounting Policies	'
	Summary of Significant Accounting Policies
	Basis of Presentation and Nature of Operations
	The unaudited condensed consolidated financial statements of Volcano Corporation (“we,” “us,” “our,” “Volcano” or the “Company”) contained in this quarterly report on Form 10-Q include our financial statements and the financial statements of our wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.
	The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. Pursuant to these rules and regulations, the Company has condensed or omitted certain information and footnote disclosures it normally includes in its annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the U.S., or GAAP. In the opinion of management, the unaudited condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows for the periods presented. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our annual report on Form 10-K for the year ended December 31, 2012.
	The results of operations for the nine months ended September 30, 2013 are not necessarily indicative of the operating results for the full fiscal year or any future periods.
	Reclassification
	Certain reclassifications have been made to the prior period condensed consolidated financial statements to conform to the current year presentation.
	Net Income (loss) Per Share
	Basic net income (loss) per share is computed by dividing consolidated net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing consolidated net income (loss) by the weighted-average number of common shares outstanding and dilutive common stock equivalent shares outstanding during the period. Our potentially dilutive shares include outstanding common stock options, unvested restricted stock units, including those with performance conditions, and incremental shares issuable upon the conversion of the Senior Convertible Notes or upon exercise of the warrants relating to the Senior Convertible Notes. Such potentially dilutive shares are excluded when the effect would be to reduce net loss per share or increase net income per share as discussed in the following paragraph. For the three and nine months ended September 30, 2013, potentially dilutive shares totaling 22.2 million and 21.7 million, respectively, have not been included in the computation of diluted net income (loss) per share, as the result would be anti-dilutive. For the three and nine months ended September 30, 2012, potentially dilutive shares totaling 2.0 million and 2.1 million, respectively, have not been included in the computation of diluted net income (loss) per share, as the result would be anti-dilutive.
	Diluted net income (loss) per common share does not include any incremental shares related to the Senior Convertible Notes for the three and nine months ended September 30, 2013 and 2012. Because the principal amount of the Senior Convertible Notes will be settled in cash upon conversion, only the conversion spread relating to the Senior Convertible Notes may be included in our calculation of diluted net income (loss) per common share. As such, the Senior Convertible Notes have no impact on diluted net income (loss) per common share until the price of our common stock exceeds the conversion price (initially $29.64 for the 2.875% Convertible Senior Notes due 2015, or the 2015 Notes and $32.83 for the 1.75% Convertible Senior Notes due 2017, or the 2017 Notes, or collectively, the Notes, subject to adjustments) of the Notes. In addition, the diluted net income (loss) per common share does not include any incremental shares related to the exercise of the warrants related to the Notes for the three and nine months ended September 30, 2013 and 2012. The warrants will not have an impact on diluted net income per common share until the price of our common stock exceeds the strike price of the warrants (initially $34.875 for the warrants issued in connection with the 2015 Notes offering and $37.59 for the warrants issued in connection with the 2017 Notes offering, subject to adjustments). When the market price of our stock exceeds the strike price, as applicable, we will include, in the diluted net income (loss) per common share calculation, the effect of the additional shares that may be issued upon exercise of the warrants using the treasury stock method to the extent the effect is not anti-dilutive.
	The call options to purchase our common stock, which we purchased to hedge against potential dilution upon conversion of the Notes, are not considered for purposes of calculating the total dilutive weighted average shares outstanding, as their effect would be anti-dilutive. Upon exercise, the call options will mitigate the dilutive effect of the Notes.
	The basic and diluted net income (loss) per common share calculations for the three and nine months ended September 30, 2013 and 2012 are as follows (in thousands, except per share data):
		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2013			2012		2013			2012
	Net (loss) income	$	(8,456	)	$	1,975	$	(14,005	)	$	5,545
	Weighted average common shares outstanding for basic	54,652			53,659		54,466			53,309
	Dilutive potential common stock outstanding:
	Stock options	—			1,376		—			1,481
	Restricted stock units	—			222		—			300
	Employee stock purchase plan	—			8		—			7
	Weighted average common shares outstanding for diluted	54,652			55,265		54,466			55,097
	Net (loss) income per share:
	Basic	$	(0.15	)	$	0.04	$	(0.26	)	$	0.1
	Diluted	$	(0.15	)	$	0.04	$	(0.26	)	$	0.1
	Recent Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board issued an accounting standard update to require entities to disclose in a single location, either in the financial statements or in the notes to the financial statements, the effects of reclassifications out of accumulated other comprehensive income. The Company adopted this accounting standard update in the first quarter of 2013 and the adoption did not have a material impact on our unaudited condensed consolidated financial statements.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2013
Business Combinations [Abstract]	'
Acquisitions	'
	Acquisitions and Acquisition-Related Items
	Pioneer Acquisition
	On August 30, 2013, we completed the acquisition of the Pioneer PlusTM diagnostic ultrasound transducer and percutaneous catheter, or Pioneer, from Medtronic, Inc. or Medtronic. The product line is an interventional medical device designed to enable the crossing of sub-total, total and chronic total occlusions within the peripheral vasculature, potentially eliminating the need for surgery. This acquisition represents a further expansion of our peripheral therapeutics product line.
	This transaction was structured as an asset purchase and was accounted for as a business combination with an aggregate purchase price of $15.0 million. The assets acquired, primarily intangible assets, were recorded at their estimated fair values as of the acquisition date. As of the date of this Quarterly Report on Form 10-Q, the Company is still finalizing the allocation of the purchase price. Changes to this allocation may occur as additional information becomes available related to the valuation of inventory, fixed assets and intangible assets.
	The acquisition was not individually or collectively considered material to the overall unaudited condensed consolidated financial statements and the results of the Company’s operations. We have included the operating results associated with the Pioneer acquisition in our unaudited condensed consolidated financial statements from the date of acquisition.
	Crux Acquisition
	On December 12, 2012 we completed the acquisition of all outstanding equity interests in Crux Biomedical, Inc., or Crux, a privately-held company engaged in the development of filter technology for the vascular, cardiovascular and interventional radiology markets. The primary reason for the acquisition was to diversify our product offerings, allow us the opportunity to better position ourselves in the peripheral vascular market and to increase our IVUS product sales. The transaction was accounted for as a business combination. The operating results of Crux from the date of acquisition were included in our unaudited condensed consolidated financial statements.
	Consideration
	We made up-front cash payments totaling $39.1 million in exchange for 100% of Crux's capital stock, of which $3.9 million is being held in escrow to satisfy claims for indemnification for certain matters made within 12 months following the closing.
	We also have a receivable for a working capital shortfall to target which is expected to be settled in 2014. The fair value of the working capital receivable represents the amount by which the working capital acquired in the transaction was less than the target working capital as stated in the Merger Agreement. The receivable will be accreted to its fair value with accretion recorded in acquisition-related items within operating expense. The receivable has a legal right of offset against milestone payments, which are expected to be paid beginning in 2014, and therefore is reflected as a contra liability. The working capital receivable was estimated to be approximately $1.2 million and the fair value of this receivable was estimated to be $900,000 at acquisition. According to the working capital audit completed in the second quarter of 2013, the working capital receivable was adjusted to be approximately $1.4 million and the fair value of this receivable was estimated to be $1.1 million at acquisition. The $200,000 adjustment is a result of additional information about facts that existed at the acquisition date that we obtained after that date, therefore this adjustment resulted in an increase in the working capital receivable and a reduction to goodwill.
	In addition, under the Merger Agreement, we previously agreed to pay a cash milestone payment of $3.0 million following the achievement of written clearance by the U.S. Food and Drug Administration, or FDA, of a 510(k) notification for the commercial sale in the United States of an inferior vena cava filter retrieval device currently being developed by Crux, provided such 510(k) notification was submitted on or before June 30, 2013. On July 1, 2013, we entered into an amendment to the Merger Agreement to extend the date by which the 510(k) notification must be submitted from June 30, 2013 to November 30, 2013 for the $3.0 million milestone payment to remain eligible to be paid. The fair value of this contingent consideration was previously estimated to be $2.9 million at acquisition. We revalued the contingent milestone payment based on the amended submission timeline and the fair value of this contingent consideration was estimated to be $2.9 million at September 30, 2013. The fair value of this contingent consideration was recorded as a current liability. We determined the fair value of the contingent consideration relative to FDA clearance using various estimates, including probabilities of success, discount rates and amount of time until the conditions of the milestone payments are met. This fair value measurement is based on significant inputs not observable in the market, representing a Level 3 measurement within the fair value hierarchy. The key assumptions used to determine the fair value of the contingent consideration include a 99% probability of success with respect to the 510(k) notification submission on or before November 30, 2013, 5% discount rate and probability adjusted milestone payment date ranges from December 29, 2013 to February 28, 2014.
	Furthermore, subject to the terms of the Merger Agreement, we may be required to make payments upon reaching various sales milestones. We estimated the contingent milestone payments to be approximately $46.6 million and the fair value of this contingent consideration was estimated to be $28.0 million at acquisition. We determined the fair value of the contingent consideration relative to the milestone payments based on commercial sales of Crux products using various estimates, including revenue projections, discount rates and amount of time until the conditions of the milestone payments are met. This fair value measurement is based on significant inputs not observable in the market, representing a Level 3 measurement within the fair value hierarchy. At September 30, 2013, for the fair value relative to the milestone payments based on the commercial sales of Crux products, the key assumptions in applying the income approach include a 14% discount rate and probability-weighted expected milestone payment ranges from $32.8 million to $70.1 million based on estimated commercial sales of Crux products ranging from $118.6 million to $304.2 million from 2014 to mid-year 2018.
	Using different valuation assumptions could result in significant differences in the fair value of the contingent consideration and accretion expense in the current or future periods.
	The following table sets forth the changes in the estimated fair value of the Company’s contingent liabilities (net with working capital receivable adjustment) measured on a recurring basis using significant unobservable inputs (Level 3) (in thousands):
		September 30, 2013
		Three Months Ended			Nine Months Ended
	Fair value measurement at beginning of period	$	31,687		$	30,231
	Change in fair value measurement included in operating expenses	881			2,337
	Contingent consideration settled	—			—
	Fair value measurement at end of period	32,568			32,568
	A reconciliation of upfront payments in accordance with the Merger Agreement to the total purchase price is presented below (in thousands):
	Base payment per agreement	$	36,000
	Reimbursement of transaction expenses incurred by Crux	3,100
	Total up-front payments	39,100
	Estimated fair value of receivable for working capital adjustment	(1,100		)
	Estimated fair value of contingent consideration	30,900
	Total purchase price	$	68,900
	Purchase price allocation
	During the nine months ended September 30, 2013, the Company recorded minor adjustments to other current assets, deferred tax asset and goodwill, as a result of updating the purchase accounting. The Company recorded the identifiable assets acquired and liabilities assumed at fair value as follows (in thousands):
		12-Dec-12
	Current assets:
	Cash and cash equivalents	$	1,474
	Other current assets	253
	Property and equipment	39
	In-process research and development	28,400
	Covenant-not-to-compete	200
	Deferred tax asset	11,281
	Total assets acquired	41,647
	Current liabilities:
	Accounts payable	(223		)
	Accrued expenses	(302		)
	Other long term payable	(97		)
	Deferred tax liability	(10,307		)
	Total liabilities assumed	(10,929		)
	Goodwill	38,182
	Net assets acquired	$	68,900
	The assets acquired and liabilities assumed were recorded at their estimated fair values as of the acquisition date. As of the date of this Quarterly Report on Form 10-Q, the Company is still finalizing the allocation of the purchase price. Changes to this allocation may occur as additional information becomes available related to indemnification claims and income taxes, with such changes recorded as an adjustment to goodwill.
	The IPR&D asset we recorded in the amount of $28.4 million represents an estimate of the fair value of in-process technology related to Crux's filter technology and retrieval device programs. The estimated fair value was determined using the multi-period excess earnings method, a variation of the income approach. The multi-period excess earnings method estimates the value of an intangible asset equal to the present value of the incremental after-tax cash flows attributable to that intangible asset. The fair value using the multi-period excess earnings method was dependent on an estimated weighted average cost of capital for Crux of 14%, which represents a rate of return that a market participant would expect for these assets.
	The excess of purchase price over the fair value amounts of the assets acquired and liabilities assumed, $38.2 million, represents the goodwill amount resulting from the acquisition, which was allocated to our medical segment and is not deductible for income tax purpose. We expect to benefit from the acquisition by expanding our product offerings to physicians thereby contributing to an expanded revenue base. Further, we expect to realize synergies by offering the products developed from the acquisition utilizing our existing sales force.
	Pro forma financial information
	The following pro forma information presents the combined results of operations for the three and nine months ended September 30, 2012 as if the acquisition of Crux had been completed as of the beginning of 2012 (in thousands, except per share data):
		Three Months Ended			Nine Months Ended
		30-Sep-12			30-Sep-12
	Revenues	93,656			279,389
	Net income	471			1,333
	Net loss per share, basic and diluted:
	Basic	$	0.01		$	0.03
	Diluted	$	0.01		$	0.02
	Shares used in computing basic and diluted net loss per share:
	Basic	53,659			53,309
	Diluted	55,265			55,097
	The pro forma results do not reflect operating efficiencies or potential cost savings which may result from the consolidation of operations.
	Sync-Rx Acquisition
On November 26, 2012, we acquired all of the outstanding equity interests in Sync-Rx Ltd., or Sync-Rx, a privately-held company, which is engaged in the development of advanced software applications that optimize and facilitate transcatheter cardiovascular interventions using automated online image processing. The Sync-Rx technology will provide us with a platform on which to build a range of advanced software features that will aid clinical decision-making by providing angiography and intra-body image enhancement, measurement and non-invasive imaging and intravascular co-registration capabilities, and future opportunities in physiology and peripheral and minimally invasive structural heart therapy guidance.
The aggregate purchase price was $17.3 million, of which $3.3 million is being held in escrow to satisfy claims for indemnification for certain matters made within 18 months following the closing. The transaction was accounted for as a business combination. We have included the operating results associated with the Sync-Rx acquisition in our unaudited condensed consolidated financial statements from the date of acquisition.
In connection with the acquisition, we recorded a contingent liability of $1.1 million related to a government grant received to develop the underlying technology. The timing of repayment of the grant is contingent upon the generation of revenues derived from the technology for which grant proceeds were received. We expect to generate revenues sufficient to repay the liability in its entirety. The grant was recorded as other long term debt at its present value using various estimates, including revenue projections, discount rate and estimated years of re-payment. This fair value measurement is based on significant inputs not observable in the market, representing a Level 3 measurement within the fair value hierarchy. At acquisition, for the fair value relative to this liability, the key assumptions in applying the income approach included an 8% discount rate and estimated commercial sales derived from the underlying technology ranging from $256.1 million to $298.3 million over the expected period of re-payment of 10 to 16 years. The long term liability will be accreted to the re-payment amount of $1.9 million plus interest, with such accretion recorded as interest expense over the expected period of re-payment. As of September 30, 2013, there were no significant changes in the range of outcomes for the contingent liability recognized as a result of the acquisition.
The preliminary purchase price allocation as of the acquisition date is summarized as follows (in thousands):
	26-Nov-12
Current assets:
Cash and cash equivalents	$	423
Accounts receivables and other current assets	72
Property and equipment	37
Developed technology	3,200
In-process research and development	1,300
Covenants not-to-compete	100
Other non-current assets	8
Deferred tax asset	2,391
Total assets acquired	7,531
Current liabilities:
Accounts payable	(56		)
Accrued expenses	(375		)
Other long-term debt	(1,100		)
Deferred tax liability	(1,150		)
Total liabilities acquired	(2,681		)
Goodwill	12,409
Net assets acquired	$	17,259
The assets acquired and liabilities assumed were recorded at their estimated fair values as of the acquisition date. As of the date of this Quarterly Report on Form 10-Q, the Company is still finalizing the allocation of the purchase price. Changes to this allocation may occur as additional information becomes available related to the valuation of intangible assets, indemnification claims and income taxes, with such changes recorded as an adjustment to goodwill.
The $3.2 million developed technology represents an estimate of the fair value of Sync-Rx's image enhancement technology, which is subject to an estimated useful life of ten years. The IPR&D asset represents an estimate of the fair value of in-process technology related to Sync-Rx's co-registration technology, which is still under development. The estimated fair values were determined using the multi-period excess earnings method, a variation of the income approach. The multi-period excess earnings method estimates the value of an intangible asset equal to the present value of the incremental after-tax cash flows attributable to that intangible asset. The rate used to discount net future after-tax cash flows to their present values was based on a discount rate of 19% for developed technology and 20% for the IPR&D. Significant factors considered in the calculation of the discount rates include the weighted average cost of capital, the internal rate of return and the weighted average return on assets, as well as the risks inherent in the development process for the technology.
The excess of purchase price over the fair value amounts of the assets acquired and liabilities assumed, $12.4 million, represents the goodwill amount resulting from the acquisition, which was allocated to our medical segment and is not deductible for income tax purpose. We expect to benefit from the acquisition by expanding our product offerings to physicians thereby contributing to an expanded revenue base. Additionally, we expect to realize synergies by offering the products developed from the acquisition utilizing our existing sales force.
Acquisition-Related Items
During the three months ended September 30, 2013, we recorded $1.3 million in acquisition-related items, including charges of $881,000 related to the change in fair value of the contingent consideration associated with the Crux acquisition, which is primarily due to the passage of time, and $358,000 in transaction costs associated with the Pioneer acquisition.
During the nine months ended September 30, 2013, we recorded $3.7 million in acquisition-related items, including charges of $2.5 million related to the change in fair value of the contingent consideration associated with the Crux acquisition, which is primarily due to the passage of time, and $810,000 in transaction costs primarily associated with the Crux and Pioneer acquisitions.

Financial_Statement_Details

Financial Statement Details	9 Months Ended
	Sep. 30, 2013
Financial Statement Details [Abstract]	'
Financial Statement Details	'
	Financial Statement Details
	Cash and Cash Equivalents and Available-for-Sale Investments
	We invest our excess funds in U.S. government securities, corporate fixed income securities, commercial paper, certificates of deposit and money market funds. As of September 30, 2013, all of our investments were classified as available-for-sale and mature within 22 months. These investments are recorded at their estimated fair value including accrued interest receivable, with unrealized gains or losses reported as a separate component of accumulated other comprehensive income or loss.
	At September 30, 2013 and December 31, 2012, available-for-sale investments are detailed as follows (in thousands):
	At September 30, 2013
			Amortized				Gross Unrealized				Gross Unrealized				Estimated
			Cost				Gains				Losses				Fair Value
	Short-term:
	Corporate debt securities		$	122,373			$	42			$	4			$	122,411
	U.S. Treasury and agency debt securities		66,377				10				20				66,367
	Short-term available-for-sale investments		$	188,750			$	52			$	24			$	188,778
	Long-term:
	Corporate debt securities		$	34,142			$	20			$	20			$	34,142
	U.S. Treasury and agency debt securities		55,026				42				—				55,068
	Long-term available for sale investments		$	89,168			$	62			$	20			$	89,210
	At December 31, 2012
			Amortized				Gross Unrealized				Gross Unrealized				Estimated
			Cost				Gains				Losses				Fair Value
	Short-term:
	Corporate debt securities		$	121,883			$	52			$	5			$	121,930
	U.S. Treasury and agency debt securities		19,020				10				—				19,030
	Short-term available-for-sale investments		$	140,903			$	62			$	5			$	140,960
	Long-term:
	Corporate debt securities		$	33,384			$	6			$	17			$	33,373
	U.S. Treasury and agency debt securities		11,010				2				—				11,012
	Long-term available for sale investments		$	44,394			$	8			$	17			$	44,385
	Available-for-sale investments that are in an unrealized loss position at September 30, 2013 and December 31, 2012 are detailed as follows (in thousands):
			At September 30, 2013
			Estimated				Gross Unrealized
			Fair Value				Losses
	Corporate debt securities		$	37,670			$	24
	U.S. Treasury and agency debt securities		40,992				20
			$	78,662			$	44
			At December 31, 2012
			Estimated				Gross Unrealized
			Fair Value				Losses
	Corporate debt securities		$	46,987			$	22
	U.S. Treasury and agency debt securities		—				—
			$	46,987			$	22
	Derivative Financial Instruments
	Foreign Currency Forward Contracts
	We are exposed to foreign currency risks through our global operations, primarily in Japan and Europe, and when we enter into transactions in non-functional currencies. Exchange rate fluctuations between the U.S. dollar and foreign currencies, primarily the yen and the euro, could adversely affect our financial results. We use derivative financial instruments to mitigate our foreign currency exposures. The purpose of our derivative financial instruments is to mitigate the effect of the exchange rate fluctuations on certain foreign currency denominated revenue, assets and liabilities. We do not enter into derivative instruments for speculative purposes.
	We enter into derivative financial instruments, principally forward contracts, to manage a portion of the foreign currency risk related to transactions in non-functional currencies. We record derivative financial instruments as either assets or liabilities in our unaudited condensed consolidated balance sheets and measure them at fair value. Certain of the derivative instruments we use to mitigate this exposure are not designated for hedge accounting treatments, and as a result, changes in their fair values are recorded in exchange rate gain (loss) in the unaudited condensed consolidated statement of operations.
	Commencing April 2013, we broadened our currency hedging program to hedge forecasted intercompany inventory transactions that are denominated in the yen and the euro. Forward contracts are used to hedge forecasted intercompany inventory transactions over specific time periods. These forward contracts are designated as cash flow hedges and have maturity dates of up to 16 months. Changes in the fair value of cash flow hedges, excluding time value of the hedges which is recorded as interest expense, are reported as a component of accumulated other comprehensive income (loss), or AOCI, within stockholders' equity. Once the underlying hedged transaction occurs, we de-designate the derivative, cease to apply hedge accounting treatment to the transaction and record any further gains or losses to exchange rate gain (loss). We evaluate hedge effectiveness at the inception of the hedge and on an ongoing basis. To the extent we experience ineffectiveness in our hedges, the gains or losses accumulated in other comprehensive income associated with the ineffective portion of the hedge are reclassified immediately into exchange rate gain (loss). We adjust the level and use of derivatives as soon as practicable after learning that an exposure has changed. We review all exposures on derivative positions on a regular basis.
	At September 30, 2013 and December 31, 2012, the notional amount of our outstanding forward contracts was $95.2 million and $64.4 million, respectively, of which $41.3 million and $0, respectively, were designated as cash flow hedges. At September 30, 2013, our outstanding forward contracts mature through January 2015.
	As of September 30, 2013, the deferred loss, net of tax, for those derivative contracts that qualified for hedge accounting treatment was $414,000, all of which will be reclassified from accumulated other comprehensive loss into cost of sales at the then-current values over the next twelve months as the underlying hedged transactions are recognized.
	The following tables summarize the location and fair values of derivative instruments on our unaudited condensed consolidated balance sheets (in thousands) at September 30, 2013 and December 31, 2012. The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not.
		As of September 30, 2013
		Asset Derivatives						Liability Derivatives
		Balance sheet location		Fair Value				Balance sheet location		Fair Value
	Derivatives Designated as Hedging Instruments
	Foreign exchange forward contracts	Other current assets		$	8			Other current liabilities		$	407
	Foreign exchange forward contracts	Other long-term assets		11				Other long-term liabilities		119
	Total Derivatives Designated as Hedging Instruments			19						526
	Derivatives Not Designated as Hedging Instruments
	Foreign exchange forward contracts	Other current assets		604				Other current liabilities		902
	Total Derivatives Not Designated as Hedging Instruments			604						902
	Total Derivatives			$	623					$	1,428
		As of December 31, 2012
		Asset Derivatives						Liability Derivatives
		Balance sheet location		Fair Value				Balance sheet location		Fair Value
	Derivatives Designated as Hedging Instruments
	Foreign exchange forward contracts	Other current assets		$	—			Other current liabilities		$	—
Foreign exchange forward contracts	Other long-term assets		—				Other long-term liabilities		—
Total Derivatives Designated as Hedging Instruments			—						—
Derivatives Not Designated as Hedging Instruments
Foreign exchange forward contracts	Other current assets		3,886				Other current liabilities		425
Total Derivatives Not Designated as Hedging Instruments			3,886						425
Total Derivatives			$	3,886					$	425
The Company has elected to present the fair value of derivative assets and liabilities within the condensed consolidated balance sheets on a gross basis even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The following table provides information (in thousands) as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.
	As of September 30, 2013
					Gross Amount Not Offset on the Balance Sheet
	Gross Amount of Recognized Assets (Liabilities)				Financial Instruments				Cash Collateral (Received) or Pledged			Net Amount
Derivative Assets
Foreign exchange forward contracts	$	623			$	(623	)		—			$	—
Derivative Liabilities
Foreign exchange forward contracts	(1,428		)		623				—			(805		)
Total	$	(805	)		—				—			(805		)
The following table summarizes the effect of our foreign exchange forward contracts on our unaudited Condensed Consolidated Statements of Operations (in thousands).
		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2013				2012				2013				2012
Derivatives Designated as Hedging Instruments
Gain (loss) recognized in other comprehensive income on foreign currency forward contracts (effective portion)		$	(727	)		$	—			$	(719	)		$	—
Gain (loss) reclassified from accumulated other comprehensive income into cost of revenue (effective portion)		(44		)		—				(44		)		—
Gain (loss) recognized in income (ineffective portion and amount excluded from effectiveness testing)		43				—				11				—
Derivatives Not Designated as Hedging Instruments
Gain (loss) recognized in exchange rate gain (loss), net		$	(996	)		$	(1,243	)		$	4,880			$	517
Options and Warrants Related to Our Convertible Notes
In connection with our convertible debt offering in December 2012, we purchased call options on our common stock. The call options give us the right to purchase up to approximately 14.0 million shares of our common stock at $32.8286 per share subject to certain adjustments that generally correspond to the adjustments to the conversion rate for the underlying debt. Additionally, we sold warrants, which give the purchasers of the warrants the right to purchase up to approximately 14.0 million shares of our common stock at $37.59 per share, subject to certain adjustments. In accordance with the authoritative guidance, we concluded that the call options and warrants were indexed to our stock. Therefore, the call options and warrants were classified as equity instruments and are not being marked to market prospectively unless certain conditions as described in the 2017 Notes occur.
In connection with our convertible debt offering in September 2010, we purchased call options on our common stock. The call options give us the right to purchase up to approximately 3.9 million shares of our common stock at $29.64 per share subject to certain adjustments that generally correspond to the adjustments to the conversion rate for the underlying debt. Additionally, we sold warrants, which give the purchaser of the warrants the right to purchase up to approximately 3.9 million shares of our common stock at $34.875 per share, subject to certain adjustments. In accordance with the authoritative guidance, we concluded that the call options and warrants were indexed to our stock. Therefore, the call options and warrants were classified as equity instruments and are not being marked to market prospectively unless certain conditions as described in the 2015 Notes occur. In December 2012, $90.0 million of the $115.0 million in aggregate principal amount of 2015 Notes were repurchased by the Company and the proportionate call option and warrant related to the convertible notes were also retired. The remaining call options give us the right to purchase up to approximately 850,000 shares of our common stock at $29.64 per share, subject to certain adjustments, and the remaining warrants give the counterparty the right to purchase up to approximately 850,000 shares of our common stock at $34.875 per share, subject to certain adjustments. The remaining call options and warrants continue to be classified as equity instruments and are not being marked to market prospectively unless certain conditions as described in the 2015 Notes occur.
Concentration of Credit Risk
Financial instruments which subject us to potential credit risk consist of our cash and cash equivalents, short-term and long-term available-for-sale investments, foreign currency derivative contracts, and trade accounts receivable.
We have established guidelines to limit our exposure to credit risk by placing investments with high credit quality financial institutions, diversifying our investment portfolio and holding investments with maturities that maintain safety and liquidity. We place our cash and cash equivalents with high credit quality financial institutions. Deposits with these financial institutions may exceed the amount of insurance provided; however, these deposits typically are redeemable upon demand. Therefore we believe the financial risks associated with these financial instruments are minimal.
Trade accounts receivable are recorded at the net invoice value and are not interest bearing. We consider receivables past due based on the contractual payment terms. We perform ongoing credit evaluations of our customers, and generally we do not require collateral on our accounts receivable. We estimate the need for allowances for potential credit losses based on historical collection activity and the facts and circumstances relevant to specific customers and we record a provision for uncollectible accounts when collection is uncertain. To date, we have not experienced significant credit related losses.
We are exposed to credit losses in the event of nonperformance by the banks with which we transact foreign currency contracts. We currently hold foreign exchange forward contracts with two counterparties. Our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We manage this credit risk by executing foreign currency contracts with counterparties that meet our minimum requirements, and monitoring the credit ratings of our counterparties on a periodic basis. As of September 30, 2013, we have minimal credit exposure from nonperformance of foreign exchange contract counterparties.
In connection with the issuance of our 2015 Notes and our 2017 Notes, we purchased call options from counterparties. Non-performance by the counterparties under these call options would potentially expose us to dilution of our common stock to the extent our stock price exceeds the conversion price (in the case of the 2015 Notes and the 2017 Notes).
We purchase integrated circuits and other key components for use in our products. For certain components, which are currently single sourced, there are relatively few sources of supply. Although we believe that other suppliers could provide similar components on comparable terms, establishment of additional or replacement suppliers cannot be accomplished quickly. Any significant supply interruption could have a material adverse effect on our business, financial condition and results of operations. For further discussion, see “Risk Factors—Our manufacturing operations are dependent upon third party suppliers, some of which are sole-sourced, which makes us vulnerable to supply problems, price fluctuations and manufacturing delays.”
Fair Value Measurements
Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Authoritative guidance establishes a three-level hierarchy for disclosure that is based on the extent and level of judgment used to estimate the fair value of assets and liabilities.
•	Level 1—Valuations based on quoted prices for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment. Our Level 1 assets consist of money market funds and U.S. Treasury and agency debt securities.
•	Level 2—Valuations based on quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data, such as alternative pricing sources with reasonable levels of price transparency. Our Level 2 assets consist of corporate debt securities including commercial paper, corporate bonds, certificates of deposit and foreign currency forward contracts.
•	Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement. Our Level 3 liability includes contingent consideration related to the Crux acquisition.
We utilize a third-party pricing service to assist us in obtaining fair value pricing for our investments. Pricing for certain securities is based on proprietary models. Inputs are documented in accordance with the fair value disclosure hierarchy. We also utilize third-party financial institutions to assist us in obtaining fair value pricing for our foreign currency forward contracts.
Contingent consideration arrangements obligate us to pay former shareholders of an acquired entity if specified future events occur or conditions are met such as the achievement of certain technological milestones or the achievement of targeted revenue milestones. We measure such liabilities using Level 3 unobservable inputs, applying the income approach, such as the discounted cash flow technique, or the probability-weighted scenario method. We used various key assumptions, such as the probability of achievement of the agreed milestones and the discount rate, in our determination of the fair value of contingent considerations. We monitor the fair value of the contingent considerations and the subsequent revisions are reflected in our Statements of Operations. For a further discussion on the key assumptions used in determining the fair value and the change in the estimated fair value of the contingent consideration during the three and nine months ended September 30, 2013, refer to Note 2, "Acquisitions and Acquisition-Related Items - Crux Acquisition".
In connection with the Sync-Rx acquisition, we recorded a contingent liability related to a government grant received to develop an underlying technology. The timing of repayment of the grant is contingent upon the generation of revenues derived from the technology for which grant proceeds were received. We measure such liability using Level 3 unobservable inputs, applying the income approach, such as the discounted cash flow technique, or the probability-weighted scenario method. The grant was recorded as other long term debt at its present value using various estimates, including revenue projections, discount rate and estimated years of re-payment. This fair value measurement is based on significant inputs not observable in the market, representing a Level 3 measurement within the fair value hierarchy. We monitor the fair value of the contingent liability and the subsequent revisions are reflected in our Statements of Operations. For a further discussion on the key assumptions used in determining the fair value, refer to Note 2, "Acquisitions and Acquisition-Related Items - Sync-Rx Acquisition".
During the three and nine months ended September 30, 2013, no transfers were made into or out of the Level 1, 2, or 3 categories.
Financial assets and liabilities measured at fair value on a recurring basis are summarized below at September 30, 2013 and December 31, 2012 (in thousands):
		Fair Value Measurements at September 30, 2013
		Total				Level 1				Level 2				Level 3
Assets:
Current:
Cash		$	54,198			$	54,198			$	—			$	—
Money market funds		157,208				157,208				—				—
Corporate debt securities		122,411				—				122,411				—
U.S. Treasury and agency debt securities		66,367				66,367				—				—
Foreign currency forward contracts		612				—				612				—
Non-current:
Corporate debt securities		34,142				—				34,142				—
U.S. Treasury and agency debt securities		55,068				55,068				—				—
Foreign currency forward contracts		11				—				11				—
Total assets measured at fair value		$	490,017			$	332,841			$	157,176			$	—
Liabilities:
Current:
Foreign currency forward contracts		$	1,309			$	—			$	1,309			$	—
Contingent consideration, current portion		2,911				—				—				2,911
Non-current:
Foreign currency forward contracts		119				—				119				—
Other long-term debt		1,207				—				—				$	1,207
Contingent consideration (1)		29,657				—				—				29,657
Total liabilities measured at fair value		$	35,203			$	—			$	1,428			$	33,775
-1	This amount is reflected net of the fair value of the working capital receivable in the amount of $1.1 million at September 30, 2013.
		Fair Value Measurements at December 31, 2012
		Total				Level 1				Level 2				Level 3
Assets:
Current:
Cash		$	41,636			$	41,636			$	—			$	—
Money market funds		288,999				288,999				—				—
Corporate debt securities		121,930				—				121,930				—
U.S. Treasury and agency debt securities		19,030				19,030				—				—
Foreign currency forward contracts		3,461				—				3,461				—
Non-current:
Corporate debt securities		33,373				—				33,373				—
U.S. Treasury and agency debt securities		11,012				11,012				—				—
Total assets measured at fair value		$	519,441			$	360,677			$	158,764			$	—
Liabilities:
Current:
Contingent consideration, current portion		$	2,908			$	—			$	—			$	2,908
Non-current:
Other long-term debt		1,088				—				$	—			$	1,088
Contingent consideration (1)		27,323				—				—				27,323
Total liabilities measured at fair value		$	31,319			$	—			$	—			$	31,319
-1	This amount is reflected net of the fair value of the working capital receivable in the amount of $907,000 at December 31, 2012.
Inventories
Inventories consist of the following (in thousands):
		September 30, 2013				31-Dec-12
Finished goods (1)		$	33,302			$	19,002
Work-in-process		12,022				15,780
Raw materials		21,643				18,029
		$	66,967			$	52,811
-1	Finished goods inventory includes consigned inventory of $6.5 million and $5.3 million at September 30, 2013 and December 31, 2012, respectively.
Intangible Assets
Intangible assets consisted of the following (in thousands):
		30-Sep-13
Intangible assets subject to amortization		Cost				Accumulated				Net				Weighted-
						Amortization								Average Life
														(in years) (1)
Developed technology		$	38,935			$	17,370			$	21,565			10.4
Licenses		7,422				7,090				332				8
Customer relationships		4,235				3,934				301				6.1
Patents and trademarks		11,037				2,521				8,516				13.2
Covenant not to compete		300				83				217				3
		61,929				30,998				30,931				10.3
Intangible assets not yet subject to amortization
In-process research and development		29,700				—				29,700				n/a
		$	91,629			$	30,998			$	60,631
		December 31, 2012
Intangible assets subject to amortization		Cost				Accumulated				Net				Weighted-
						Amortization								Average Life
														(in years) (1)
Developed technology		$	27,051			$	17,408			$	9,643			8.8
Licenses		7,345				6,709				636				10
Customer relationships		4,177				3,756				421				6
Patents and trademarks		8,029				2,114				5,915				13.2
Covenant not to compete		300				8				292				3
		46,902				29,995				16,907				9.4
Intangible assets not yet subject to amortization
In-process research and development		33,750				—				33,750				n/a
		$	80,652			$	29,995			$	50,657
-1	Weighted average life of intangible assets is presented excluding fully amortized assets.
At September 30, 2013, future amortization expense related to our intangible assets subject to amortization is expected to be as follows (in thousands):
2013	$	1,068
2014	4,066
2015	3,993
2016	3,725
2017	3,212
Thereafter	14,867
	$	30,931
Intangible Assets Impairment
The Company reviews intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an intangible asset or asset group may not be recoverable. The Company also assesses the impairment of in-process research and development, or IPR&D, assets annually and whenever events or changes in circumstances indicate that the carrying amount may be impaired.
During the third quarter of 2013, $4.6 million of intangible assets, including IPR&D and developed technology, were impaired in connection with a restructuring plan (see Note 3 "Financial Statement Details - Restructuring Activity - Third Quarter of 2013" below).
Restructuring Activity
Second Quarter of 2013
During the second quarter of 2013, our management approved plans to consolidate and transition our manufacturing resources related to the manufacture of disposables to Costa Rica and 27 production employees in our manufacturing facility in California were impacted by this plan in June 2013. One-time benefits to affected employees included a separation agreement including severance payments and continuing medical benefits. Consistent with authoritative guidance, we accrued the costs of one-time termination benefits to employees who were not required to render service beyond a minimum retention period of 60 days. As a result, we recorded approximately $258,000 in restructuring charges in June 2013.
We anticipate more employees in our manufacturing facility in the U.S. will be impacted and we expect to substantially complete this restructuring plan in 2014. We cannot estimate the future restructuring cost at this time as the total number of employees who will be impacted has not yet been determined.
Third Quarter of 2013
During the third quarter of 2013, our management evaluated various development projects, product lines and functional areas in an effort to assess how to better align resources to our key business strategies and improve operating efficiencies. At September 30, 2013, in connection with the preparation of our financial statements, our management concluded that it is more likely than not the Forward-Looking IVUS, or FL.IVUS and Forward-Looking Intra-Cardiac Echo, or FL.ICE, development programs and the commercial sale of the ReFLOW Aspiration Catheter, or ReFLOW, product line will be discontinued. As such, these assets were impaired with the resulting charge recorded in restructuring charges in the statement of operations in the third quarter of 2013. The technologies associated with these programs were acquired in various business combinations and resulted in IPR&D and developed technologies that were capitalized at the time of acquisition with a carrying value of $4.6 million as of September 30, 2013.
Subsequent Event - Fourth Quarter of 2013
During the fourth quarter of 2013, our management further evaluated our development projects and functional areas in an effort to reprioritize and reallocate our resources within our distribution, research and development, and clinical programs to focus on development and commercial efforts that we believe better advance our key strategies, and in November 2013, we made the decision to discontinue our FL.IVUS, FL.ICE, and Optical Coherence Tomography, or OCT, intravascular coronary imaging development programs and discontinue our ReFLOW product line. The key elements under this restructuring plan include the discontinuation of development programs for our FL.IVUS, FL.ICE and OCT intravascular coronary imaging development programs, the termination of the commercial sale of the ReFLOW product line, and a modest reorganization of several functional areas and business units within the Company.
We expect to incur additional restructuring charges of approximately up to $14.9 million in the fourth quarter of 2013 and early 2014 in connection with the discontinuation of our OCT intravascular coronary imaging, FL.IVUS and FL.ICE programs and the discontinuation of our ReFLOW product line, including costs associated from the related reorganization of several areas within the Company, which include employee termination costs of approximately up to $2.9 million, asset impairments of approximately up to $4.1 million and other restructuring related costs of approximately up to $7.9 million. Of the estimated $14.9 million of restructuring charges, we estimate that approximately up to $10.7 million will be comprised of future cash expenditures.
Debt
In December 2012, we issued $460 million aggregate principal amount of 1.75% Convertible Senior Notes due 2017 ("2017 Notes"), in an offering registered under the Securities Act of 1933, as amended. Interest is payable semiannually in arrears on June 1 and December 1, commencing on June 1, 2013.
In September 2010, we issued $115 million aggregate principal amount of 2.875% Convertible Senior Notes due 2015 ("2015 Notes"), in an offering registered under the Securities Act of 1933, as amended. Interest is payable semiannually in arrears on March 1 and September 1, commencing on March 1, 2011. In December 2012, in connection with the issuance of the 2017 Notes, we repurchased $90 million of the $115 million in aggregate principal amount of the 2015 Notes.
The carrying values of the liability and equity components of both the 2017 Notes and the 2015 Notes are reflected in our unaudited condensed consolidated balance sheets as follows (in thousands):
		September 30, 2013				December 31, 2012
Long-term debt:
2.875% Convertible Senior Notes due 2015:
Principal amount		$	25,000			$	25,000
Unamortized discount of liability component		(2,078		)		(2,830		)
Unamortized debt issuance costs		(234		)		(326		)
Carrying value of liability component		22,688				21,844
1.75% Convertible Senior Notes due 2017:
Principal amount		460,000				460,000
Unamortized discount of liability component		(76,914		)		(88,536		)
Unamortized debt issuance costs		(9,563		)		(11,008		)
Carrying value of liability component		373,523				360,456
Total long-term debt		$	396,211			$	382,300
Equity—net carrying value
2.875% Convertible Senior Notes due 2015		$	452			$	452
1.75% Convertible Senior Notes due 2017		89,415				89,415
The fair values of the Notes, which are all Level 2 measurements, are summarized as follows (in thousands):
	September 30, 2013				December 31, 2012
2.875% Convertible Senior Notes due 2015	$	26,693			$	26,950
1.75% Convertible Senior Notes due 2017	479,325				462,850
Total	$	506,018			$	489,800

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2013
Loss Contingency [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	Litigation-LightLab
	On January 7, 2009, LightLab Imaging, Inc., or LightLab, which was acquired by St. Jude Medical, Inc., or St. Jude, in 2010, filed a complaint against us and our wholly owned subsidiary, Axsun, in the Superior Court of Massachusetts, Suffolk County, seeking injunctive relief and unspecified damages (the Massachusetts Action). The complaint included allegations that Volcano interfered with an agreement between Axsun and Lightlab and with LightLab's advantageous business relationship with Axsun, breach of contract by Axsun, that Axsun and Volcano misappropriated LightLab's confidential information and trade secrets, and violated Chapter 93A, a Massachusetts statute that provides for recovery of up to three times damages plus attorney's fees (93A).
	The Judge ordered that the trial in the Massachusetts Action proceed in four separate phases, with a jury trial first on liability, followed by a jury trial on damages, and then non-jury hearings on liability under 93A and on injunctive relief.
	The jury in the trial on liability returned a verdict on February 4, 2010 that included findings that the contract specifications for the lasers Axsun supplies and previously supplied to LightLab are trade secrets of LightLab, that Axsun agreed not to sell any tunable lasers to Volcano for any purpose or to third parties for use in cardiology imaging during the exclusivity period in the contract, and that Axsun breached its contract with LightLab. The jury further found that Volcano intentionally interfered with LightLab's advantageous business relationship with Axsun.
	In lieu of conducting a trial on damages, the parties agreed and stipulated in April 2010 that the sum of $200,000 would be treated as if it were the jury's verdict against the defendants for damages (the Stipulation).
	The injunctive relief phase of the Massachusetts Action commenced in April 2010. In a ruling issued in October 2010, the Court rejected LightLab's claims for protection of five alleged trade secrets relating to laser technologies, and denied all of LightLab's requests for permanent injunctions with respect to those trade secrets.
	In a summary judgment ruling issued January 26, 2011, the Court rejected the remainder of LightLab's claims for protection of its remaining trade secrets, and denied all of LightLab's claims for permanent injunctions with respect to those trade secrets.
	In a ruling issued January 28, 2011, the Court found that Volcano and Axsun violated 93A, and awarded LightLab additional damages of $400,000 and reasonable attorneys' fees.
	On February 10, 2011, and on April 7, 2011, the Court entered a Final Judgment and an Amended Final Judgment, respectively, in the Massachusetts Action: a) in favor of Volcano and Axsun on LightLab's claims for trade secret misappropriation on items 1-30 on LightLab's list of alleged trade secrets, b) ordered Volcano and Axsun to collectively pay $600,000 in damages and $4.5 million in attorneys' fees, c) in favor of LightLab on its claims against Axsun for breach of contract, breach of implied covenant of good faith and fair dealing, for violation of 93A, and misappropriation of trade secrets for disclosing three particular items to Volcano in December 2008 - the specifications for the two lasers provided by Axsun to LightLab and one Axsun laser prototype made in 2008, d) in favor of LightLab on its claims against Volcano for intentional interference with a contract and advantageous business relationship, unjust enrichment, violation of 93A, and misappropriation of trade secrets for the same three trade secrets described above. In addition, the Court denied a majority of LightLab's requested injunctions, and entered limited injunctive relief, none of which management believes have a material effect upon Volcano. The Final Judgment and Amended Final Judgment are substantially similar. The Amended Final Judgment corrects non-substantive clerical errors.
	LightLab has appealed various decisions of the Court including, a) the Court's pre-trial rulings excluding certain lost profits damages evidence that LightLab sought to introduce at trial; b) the Court's decisions adverse to LightLab's claims for trade secret misappropriation in items 1-30 of LightLab's alleged list of trade secrets, including various rulings requiring evidence of use or intent to use as a prerequisite for injunctive relief; c) the Court's post-trial decisions denying permanent injunctive relief that LightLab requested as terms of the Final Judgment; and; d) the denial of LightLab's motion to alter or amend the Final Judgment, which motion sought to obtain additional declaratory relief barring Axsun from “supplying” tunable lasers to Volcano. Volcano and Axsun did not cross appeal the Amended Final Judgment, and on July 5, 2011, Volcano and Axsun satisfied their payment obligations under the Amended Final Judgment by making a payment to Lightlab in the amount of approximately $5.4 million. The Massachusetts Supreme Judicial Court has agreed to hear LightLab's appeal. The appeal will be heard on December 2, 2013.
	In February 2010, Volcano and Axsun commenced an action in the Delaware Chancery Court, or the Chancery Court Action, against LightLab seeking a declaration of Volcano and Axsun's rights with respect to certain OCT technology, the High Definition Swept Source. LightLab then filed a counter-claim that included a claim against Axsun and Volcano for violations of 93A. The 93A counterclaim has been stayed pending further action by the Chancery Court. This case has been stayed until such time as Volcano has achieved certain development and regulatory milestones.
	Additionally, on May 24, 2011, LightLab commenced a separate action in Delaware Chancery Court, or the Second Chancery Court Action, against Volcano and Axsun alleging that Axsun is inappropriately assisting Volcano in the development of a third-party laser. The complaint seeks injunctive relief and unspecified damages. After Volcano and Axsun moved to dismiss the Second Chancery Court Action, LightLab filed an amended complaint against Volcano and Axsun, adding additional allegations regarding misappropriation of trade secrets. This case has been stayed indefinitely.
	In January 2013, Lightlab filed a motion with the Delaware Chancery Court requesting the Chancery Court lift the stays in the Chancery Court Actions in order for Lightlab to file motions for injunctive relief. In April 2013, the Chancery Court denied this motion.
	Litigation - St. Jude Medical
	On July 27, 2010, St. Jude Medical filed a lawsuit against Volcano in federal district court in Delaware (collectively, with the counterclaims described below, the Delaware Patent Action), alleging that our pressure guide wire products infringe five patents owned by St. Jude Medical. St. Jude Medical is seeking injunctive relief and monetary damages. This action does not involve OCT technology and is separate from the Massachusetts Action.
	On September 20, 2010, Volcano filed its response, in which we denied the allegations that our PrimeWire ® products infringe any valid claim of St. Jude Medical's asserted patents. In addition, Volcano filed a counterclaim in which we have alleged that St. Jude Medical's PressureWire ® products and its RadiAnalyzer ® Xpress product infringe three Volcano patents. In our counterclaim, Volcano is seeking injunctive relief and monetary damages. A trial on the St. Jude Medical patents was scheduled for October 15, 2012 and a trial on Volcano's patents was scheduled for October 22, 2012.
	On October 12, 2012, the court entered summary judgment for Volcano with respect to one of St. Jude Medical's asserted patents. On October 19, 2012, a jury found in favor of Volcano on the remaining four St. Jude Medical patents, finding that two of the patents were invalid and that Volcano did not infringe two of the patents. On October 22, 2012, Volcano voluntarily dismissed its claims against St. Jude Medical with respect to one of Volcano's patents. On October 25, 2012, a jury found in favor of St. Jude Medical with respect to Volcano's asserted patents. In conjunction with the trial, St. Jude Medical agreed that previous versions of its PressureWire® products infringed Volcano's 6,976,965 patent (a pressure sensing guide wire patent). Post-trial motions are pending or remain available to the parties in the case. A trial on damages has been scheduled for January 2014.
	On April 9, 2012, St. Jude Medical, Cardiology Division, Inc., St. Jude Medical Systems AB and St. Jude Medical S.C. filed a sealed complaint in the United States District Court for the District of Delaware alleging that Volcano Corporation infringes United States Patent No. 6,565,514. No trial date has been set in this case.
	On April 16, 2013, Volcano filed suit in Federal District Court in Delaware against St. Jude Medical, Cardiovascular and Ablation Technologies Division, Inc., St. Jude Medical, Cardiology Division, Inc., St. Jude Medical, U.S. Division, St. Jude Medical S.C. Inc., and St. Jude Medical Systems AB, (collectively, “St. Jude”) for infringement of Volcano's recently issued United States Patent Nos. 8,419,647 and 8,419,648 both entitled “Ultra Miniature Pressure Sensor.” Volcano's complaint accuses St. Jude's PressureWire™ Certus and PressureWire™ Aeris cardiac pressure sensing guide wire products (the “Accused Guide Wires”) and St. Jude's RadiAnalyzer™ Xpress Measurement System, Ilumien™ PCI Optimization System and Quantien™ Integrated FFR Platform, which are used with the Accused Guide Wires, of infringing the patented methods of United States Patent No. 8,419,647. Volcano's complaint also accuses the Accused Guide Wires of infringing the patented device claims of United States Patent No. 8,419,648. No trial date has been set for this case.
	Litigation - CardioSpectra
	On March 27, 2012, Christopher E. Banas, et al., filed a lawsuit against Volcano in federal district court in the Northern District of California, alleging claims for breach of contract, breach of fiduciary duty, and breach of the implied covenant of good faith and fair dealing based on Volcano's acquisition of CardioSpectra in 2007. Specifically, plaintiffs assert that Volcano has failed to comply with the terms and the alleged implied obligations of the Merger Agreement relating to potential milestone payments. CardioSpectra was in the business of developing OCT technology; however, this litigation is separate from the Massachusetts Action.
	On May 14, 2012, Volcano moved to dismiss the complaint in its entirety. The motion sought to dismiss the breach of fiduciary duty and implied covenant claims without leave for amendment, and to dismiss the breach of contract claim with leave to amend. By order dated August 6, 2012, the Court granted Volcano's motion as to all issues with leave to amend. The plaintiffs filed a Second Amended Complaint on August 20, 2012, which included a single claim for breach of the Merger Agreement. In addition, the plaintiffs identified in the Second Amended Complaint are listed as Christopher E. Banas and Paul Castella in their respective capacities as Shareholder Representatives under the Merger Agreement. Volcano answered the Second Amended Complaint on September 4, 2012, and in the same document Volcano asserted several affirmative defenses. A trial date has been scheduled for May 27, 2014 for this matter.
	Litigation - Other
	In November 2012, we became aware through newspaper reports in the Italian media that a then-current and a former employee of ours were under criminal investigation for an alleged violation of Italian anti-bribery laws. We also learned that Volcano Europe B.V.B.A., our wholly-owned subsidiary, had temporarily been prohibited from establishing new contractual relationships with hospitals that are part of the Italian national health system. Following a court hearing, the temporary prohibition was lifted. The Italian public prosecutor has requested that such prohibition be reinstituted. This request is pending. The Italian public prosecutor is alleging that the approximately €5,000 that we paid to an Italian state-employed physician for conducting a training session was paid in an effort to influence the outcome of a clinical trial.
	The Company believes the lawsuits and other matter described above are without merit, and intends to vigorously defend against or prosecute, as applicable, the matters described above.
	We may also be a party to various other claims in the normal course of business or become aware of allegations involving us or our employees. Legal fees and other costs associated with investigating, assessing and responding to such claims and allegations are expensed as incurred and were not material in any period reported. Additionally, we assess, in conjunction with our legal counsel, the need to record a liability for litigation and contingencies. Reserve estimates are recorded when and if it is determined that a loss related matter is both probable and reasonably estimable. Any provisions are reviewed at least quarterly and are adjusted to reflect the impact and status of settlements, rulings, advice of counsel and other information and events pertinent to a particular matter. Based on its experience, the Company also believes that the damage amounts claimed in the lawsuits disclosed above are not a meaningful indicator of the Company's potential liability. At this time, we are not able to predict or estimate the ultimate outcome or range of possible losses relating to the lawsuits, claims or counterclaims described above. However, we believe that the ultimate disposition of these matters, individually and in the aggregate, including the lawsuits, claims and counterclaims discussed above, will not have a material impact on our consolidated results of operations, financial position or cash flows. Our evaluation of the likely impact of these matters could change in the future, as litigation is inherently unpredictable, and unfavorable outcomes and/or defense costs, depending upon the amount and timing, could have a material adverse effect on our results of operations, financial position, or cash flows in future periods.
	Operating Leases
	Rent expense for our facilities leases is being recognized on a straight-line basis over the respective minimum lease terms.
	Commitments
	We have obligations under non-cancelable purchase commitments. The majority of these obligations related to inventory, primarily raw materials. At September 30, 2013, the future minimum payments under these non-cancelable purchase commitments totaled $29.7 million. Approximately $23.3 million of these commitments will require payment in 12 months, of which $16.4 million of these commitments will require payment prior to December 31, 2013. The remaining amount will require payments on various dates through 2016.
	We have commitments to provide funding of $4.6 million to a clinical study conducted by a third-party and at September 30, 2013, we have a remaining obligation of up to $2.1 million. We will be billed as services are performed under the agreement. In addition, we have entered into agreements with other third parties to sponsor clinical studies. Generally, we contract with one or more clinical research sites for a single study and no one agreement is material to our consolidated results of operations or financial condition. We are usually billed as services are performed based on enrollment and are required to make payments over periods ranging from less than one year up to three years. Our actual payments under these agreements will vary based on enrollment.
	Indemnification
	Our supplier, distributor and collaboration agreements generally include certain provisions for indemnification against liabilities if our products are recalled, infringe a third party’s intellectual property rights or cause bodily injury due to alleged defects in our products. In addition, we have agreements with our present and former directors and executive officers indemnifying them against liabilities arising from service in their respective capacities to Volcano. We maintain directors’ and officers’ insurance policies that may limit our exposure to such liabilities. To date, we have not incurred any material costs as a result of such indemnifications and have not accrued any liabilities related to such obligations in the accompanying unaudited condensed consolidated financial statements.
	Sole source suppliers
	We rely on a number of sole source suppliers to supply transducers, substrates and processing for our scanners used in our catheters. We do not carry significant inventory of transducers, substrates or scanner subassemblies. If we had to change suppliers, we expect that it would take 6 to 24 months to identify appropriate suppliers, complete design work and undertake the necessary inspections and testing before the new transducers and substrates would be available. We are not parties to supply agreements with these suppliers but instead use purchase orders as needed.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity	'
	Stockholders’ Equity
	Equity Compensation Plans
	Our Amended and Restated 2005 Equity Compensation Plan, or the 2005 Amended Plan provides for an aggregate of 21,572,558 shares of our common stock that may be issued or transferred to our employees, non-employee directors and consultants, including an increase of 5,360,000 shares which was approved by our stockholders on May 15, 2013.
	At September 30, 2013, we have granted stock options, RSUs and performance-based RSUs under the 2005 Amended Plan. Stock options previously granted under the 2000 Long Term Incentive Plan that are canceled or expired will increase the shares available for grant under the 2005 Amended Plan. In addition, employees have purchased shares of the Company’s common stock under the 2007 Employee Stock Purchase Plan, or the Purchase Plan. At September 30, 2013, 6,724,993 shares and 55,911 shares remained available to grant under the 2005 Amended Plan and the Purchase Plan, respectively.
	Fair Value Assumptions
	The fair value of each stock option is estimated on the date of grant using the Black-Scholes model utilizing the following weighted-average assumptions:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Risk-free interest rate	1.3		%	0.7		%	0.8		%	0.8		%
	Expected life (years)	4.6			4.1			4.2			4.1
	Estimated volatility	41.9		%	46.1		%	39.3		%	47		%
	Expected dividends	None			None			None			None
	Weighted-average grant date fair value	$	7.34		$	10.89		$	7.44		$	10.83
	The risk-free interest rate for periods within the contractual life of the stock option is based on the implied yield available on U.S. Treasury constant maturity securities with the same or substantially equivalent remaining terms at the time of grant. We use our historical stock option exercise experience to estimate the expected term of our stock options. We utilize the volatility of our own common stock in determining the grant date fair value. We use a zero value of the expected dividend value factor since we have not declared any dividends in the past and we do not anticipate declaring any dividends in the foreseeable future.
	The first offering period under the Purchase Plan commenced in September 2007. The fair value of each purchase option under the Purchase Plan is estimated at the beginning of each purchase period using the Black-Scholes model utilizing the following weighted-average assumptions:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Risk-free interest rate	0.1		%	0.1		%	0.1		%	0.1		%
	Expected life (years)	0.5			0.5			0.5			0.5
	Estimated volatility	29.6		%	36.8		%	30		%	39.1		%
	Expected dividends	None			None			None			None
	Fair value of purchase right	$	5.53		$	7.07		$	5.21		$	7.32
	The computation of the expected volatility assumption used in the Black-Scholes model for purchase rights is based on the trading history of our common stock. The expected life assumption is based on the six-month term of each offering period. The risk-free interest rate is based on the U.S. Treasury constant maturity securities with the same or substantially equivalent remaining term in effect at the beginning of the offering period. We use a zero value for the expected dividend value factor since we have not declared any dividends in the past and we do not anticipate declaring any dividends in the foreseeable future.
	Stock-Based Compensation Expense
	The following table sets forth stock-based compensation expense included in our unaudited condensed consolidated statements of operations (in thousands):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Cost of revenues	$	196		$	202		$	583		$	515
	Selling, general and administrative	3,592			3,331			10,152			9,606
	Research and development	462			403			1,363			1,307
		$	4,250		$	3,936		$	12,098		$	11,428

Segment_and_Geographic_Informa

Segment and Geographic Information	9 Months Ended
	Sep. 30, 2013
Segment And Geographic Information [Abstract]	'
Segment And Geographic Information	'
	Segment and Geographic Information
	Our chief operating decision-maker reviews financial information presented on a consolidated basis, accompanied by disaggregated information about segment revenues by product and geographic region for purposes of making operating decisions and assessing financial performance. We have two reporting segments, the first being the medical segment which include the manufacture, sale, discovery, development and commercialization of products for the diagnosis of atherosclerosis in the coronary arteries and peripheral vascular system. In addition we have an industrial segment which includes the discovery, development, manufacture and sale of micro-optical spectrometers and optical channel monitors to telecommunications and other industrial companies.
	We do not assess the performance of our segments on other measures of income or expense, such as depreciation and amortization, operating income or net income. We do not produce reports for, or measure the performance of, our segments on any asset-based metrics. Therefore, segment information is presented only for revenues by product.
	The following table sets forth our revenues by segment and product (in thousands):
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Medical segment:
	Consoles	$	10,964	$	9,679	$	31,469	$	28,529
	Single-procedure disposables:
	IVUS	46,024		48,574		143,869		153,683
	FM	27,869		24,585		83,345		67,652
	Other	8,809		7,825		25,725		21,286
	Sub-total medical segment	93,666		90,663		284,408		271,150
	Industrial segment	2,143		2,993		5,976		8,239
		$	95,809	$	93,656	$	290,384	$	279,389
	The following table sets forth our revenues by geography expressed as dollar amounts (in thousands):
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Revenues (1):
	United States	$	46,673	$	44,083	$	139,076	$	130,152
	Japan	26,368		29,699		82,292		90,025
	Europe, the Middle East and Africa	17,371		13,491		51,512		42,507
	Rest of world	5,397		6,383		17,504		16,705
		$	95,809	$	93,656	$	290,384	$	279,389
	-1	Revenues are attributed to geographies based on the location of the customer, except for shipments to original equipment manufacturers, which are attributed to the country of origin of the equipment distributed.
	At September 30, 2013, approximately 50% of our long-lived assets, excluding financial assets, are located in the U.S., approximately 38% are located in Costa Rica, approximately 8% are located in Japan, and approximately 4% are located in our remaining geographies. At December 31, 2012, approximately 42% of our long-lived assets, excluding financial assets, were located in the U.S., approximately 42% were located in Costa Rica, approximately 12% were located in Japan, and approximately 4% were located in our remaining geographies.
	At September 30, 2013 and December 31, 2012, goodwill of $53.1 million and $51.6 million has been allocated entirely to our medical segment.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	Income taxes are determined using an estimated annual effective tax rate applied against income, and then adjusted for the tax impacts of certain discrete items. The Company recorded an income tax benefit of $10.2 million during the nine months ended September 30, 2013, resulting in an effective benefit rate of 42.0%. We recorded income tax expense of $4.3 million during the nine months ended September 30, 2012, resulting in an income tax expense rate of 43.6%. The Company updates its annual effective income tax rate each quarter and if the estimated effective income tax rate changes, a cumulative adjustment is made.
	During the quarter ended March 31, 2013, federal legislation was enacted within the U.S. that retroactively allowed a research and development (R&D) tax credit for all of 2012 and extended the R&D credit through the twelve months ending December 31, 2013. Because this legislation was enacted in 2013, the full benefit of the credit related to 2012's activities was recognized during the nine months ended September 30, 2013. In the absence of the 2012 R&D credit, our effective benefit tax rate for the nine months ended September 30, 2013 would have been 38.0%.
	The annual effective income tax rate for 2013, exclusive of the impact of the R&D tax credit discussed above, is expected to be higher than the U.S. federal statutory rate of 35.0% primarily due to state income taxes, net of federal benefit, estimates for certain non-deductible expenses and foreign rate differentials.
	The Company evaluates the realizability of the deferred tax assets on a jurisdictional basis at each reporting date. Accounting for income taxes guidance requires that a valuation allowance be established when it is more-likely-than-not that all or a portion of the deferred tax assets will not be realized. As part of the evaluation, the Company reviews both positive and negative evidence to determine if a valuation allowance is needed.
	The Company's review of positive evidence included the review of in-process tax planning strategies, favorable historical results and forecasted pre-tax income. Negative evidence includes a forecasted current year loss and near-term industry challenges. In circumstances where there is sufficient negative evidence indicating that the deferred tax assets are not more-likely-than-not realizable, the Company establishes a valuation allowance. The Company determined that there was sufficient evidence to establish that the Company’s current recorded valuation allowance against certain deferred tax assets remains reasonable. The Company will monitor the need for additional valuation allowances at each quarter in the future and if the negative evidence outweighs the positive evidence an allowance will be recorded.

Summary_Of_Significant_Account1

Summary Of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis Of Presentation And Principles Of Consolidation	'
	The unaudited condensed consolidated financial statements of Volcano Corporation (“we,” “us,” “our,” “Volcano” or the “Company”) contained in this quarterly report on Form 10-Q include our financial statements and the financial statements of our wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.
	The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. Pursuant to these rules and regulations, the Company has condensed or omitted certain information and footnote disclosures it normally includes in its annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the U.S., or GAAP. In the opinion of management, the unaudited condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows for the periods presented. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our annual report on Form 10-K for the year ended December 31, 2012.
Our Company	'
	The results of operations for the nine months ended September 30, 2013 are not necessarily indicative of the operating results for the full fiscal year or any future periods.
Net Income (Loss) Per Share	'
	Net Income (loss) Per Share
	Basic net income (loss) per share is computed by dividing consolidated net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing consolidated net income (loss) by the weighted-average number of common shares outstanding and dilutive common stock equivalent shares outstanding during the period. Our potentially dilutive shares include outstanding common stock options, unvested restricted stock units, including those with performance conditions, and incremental shares issuable upon the conversion of the Senior Convertible Notes or upon exercise of the warrants relating to the Senior Convertible Notes. Such potentially dilutive shares are excluded when the effect would be to reduce net loss per share or increase net income per share as discussed in the following paragraph. For the three and nine months ended September 30, 2013, potentially dilutive shares totaling 22.2 million and 21.7 million, respectively, have not been included in the computation of diluted net income (loss) per share, as the result would be anti-dilutive. For the three and nine months ended September 30, 2012, potentially dilutive shares totaling 2.0 million and 2.1 million, respectively, have not been included in the computation of diluted net income (loss) per share, as the result would be anti-dilutive.
	Diluted net income (loss) per common share does not include any incremental shares related to the Senior Convertible Notes for the three and nine months ended September 30, 2013 and 2012. Because the principal amount of the Senior Convertible Notes will be settled in cash upon conversion, only the conversion spread relating to the Senior Convertible Notes may be included in our calculation of diluted net income (loss) per common share. As such, the Senior Convertible Notes have no impact on diluted net income (loss) per common share until the price of our common stock exceeds the conversion price (initially $29.64 for the 2.875% Convertible Senior Notes due 2015, or the 2015 Notes and $32.83 for the 1.75% Convertible Senior Notes due 2017, or the 2017 Notes, or collectively, the Notes, subject to adjustments) of the Notes. In addition, the diluted net income (loss) per common share does not include any incremental shares related to the exercise of the warrants related to the Notes for the three and nine months ended September 30, 2013 and 2012. The warrants will not have an impact on diluted net income per common share until the price of our common stock exceeds the strike price of the warrants (initially $34.875 for the warrants issued in connection with the 2015 Notes offering and $37.59 for the warrants issued in connection with the 2017 Notes offering, subject to adjustments). When the market price of our stock exceeds the strike price, as applicable, we will include, in the diluted net income (loss) per common share calculation, the effect of the additional shares that may be issued upon exercise of the warrants using the treasury stock method to the extent the effect is not anti-dilutive.
	The call options to purchase our common stock, which we purchased to hedge against potential dilution upon conversion of the Notes, are not considered for purposes of calculating the total dilutive weighted average shares outstanding, as their effect would be anti-dilutive. Upon exercise, the call options will mitigate the dilutive effect of the Notes.
	The basic and diluted net income (loss) per common share calculations for the three and nine months ended September 30, 2013 and 2012 are as follows (in thousands, except per share data):
		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2013			2012		2013			2012
	Net (loss) income	$	(8,456	)	$	1,975	$	(14,005	)	$	5,545
	Weighted average common shares outstanding for basic	54,652			53,659		54,466			53,309
	Dilutive potential common stock outstanding:
	Stock options	—			1,376		—			1,481
	Restricted stock units	—			222		—			300
	Employee stock purchase plan	—			8		—			7
	Weighted average common shares outstanding for diluted	54,652			55,265		54,466			55,097
	Net (loss) income per share:
	Basic	$	(0.15	)	$	0.04	$	(0.26	)	$	0.1
	Diluted	$	(0.15	)	$	0.04	$	(0.26	)	$	0.1
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board issued an accounting standard update to require entities to disclose in a single location, either in the financial statements or in the notes to the financial statements, the effects of reclassifications out of accumulated other comprehensive income. The Company adopted this accounting standard update in the first quarter of 2013 and the adoption did not have a material impact on our unaudited condensed consolidated financial statements.

Summary_Of_Significant_Account2

Summary Of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Schedule Of Basic And Diluted Net Income (Loss) Per Common Share Calculations	'
	The basic and diluted net income (loss) per common share calculations for the three and nine months ended September 30, 2013 and 2012 are as follows (in thousands, except per share data):
		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2013			2012		2013			2012
	Net (loss) income	$	(8,456	)	$	1,975	$	(14,005	)	$	5,545
	Weighted average common shares outstanding for basic	54,652			53,659		54,466			53,309
	Dilutive potential common stock outstanding:
	Stock options	—			1,376		—			1,481
	Restricted stock units	—			222		—			300
	Employee stock purchase plan	—			8		—			7
	Weighted average common shares outstanding for diluted	54,652			55,265		54,466			55,097
	Net (loss) income per share:
	Basic	$	(0.15	)	$	0.04	$	(0.26	)	$	0.1
	Diluted	$	(0.15	)	$	0.04	$	(0.26	)	$	0.1

Acquisitions_Tables

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2013
Crux Acquisition [Member]	'
Business Acquisition [Line Items]	'
Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]	'
	The following table sets forth the changes in the estimated fair value of the Company’s contingent liabilities (net with working capital receivable adjustment) measured on a recurring basis using significant unobservable inputs (Level 3) (in thousands):
		September 30, 2013
		Three Months Ended			Nine Months Ended
	Fair value measurement at beginning of period	$	31,687		$	30,231
	Change in fair value measurement included in operating expenses	881			2,337
	Contingent consideration settled	—			—
	Fair value measurement at end of period	32,568			32,568
Business Acquistions, Reconciliation Of Upfront Payments	'
	A reconciliation of upfront payments in accordance with the Merger Agreement to the total purchase price is presented below (in thousands):
	Base payment per agreement	$	36,000
	Reimbursement of transaction expenses incurred by Crux	3,100
	Total up-front payments	39,100
	Estimated fair value of receivable for working capital adjustment	(1,100		)
	Estimated fair value of contingent consideration	30,900
	Total purchase price	$	68,900
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	'
	The Company recorded the identifiable assets acquired and liabilities assumed at fair value as follows (in thousands):
		12-Dec-12
	Current assets:
	Cash and cash equivalents	$	1,474
	Other current assets	253
	Property and equipment	39
	In-process research and development	28,400
	Covenant-not-to-compete	200
	Deferred tax asset	11,281
	Total assets acquired	41,647
	Current liabilities:
	Accounts payable	(223		)
	Accrued expenses	(302		)
	Other long term payable	(97		)
	Deferred tax liability	(10,307		)
	Total liabilities assumed	(10,929		)
	Goodwill	38,182
	Net assets acquired	$	68,900
Business Acquisition, Pro Forma Information	'
	The following pro forma information presents the combined results of operations for the three and nine months ended September 30, 2012 as if the acquisition of Crux had been completed as of the beginning of 2012 (in thousands, except per share data):
		Three Months Ended			Nine Months Ended
		30-Sep-12			30-Sep-12
	Revenues	93,656			279,389
	Net income	471			1,333
	Net loss per share, basic and diluted:
	Basic	$	0.01		$	0.03
	Diluted	$	0.01		$	0.02
	Shares used in computing basic and diluted net loss per share:
	Basic	53,659			53,309
	Diluted	55,265			55,097
Synch-Rx Acquisition [Member]	'
Business Acquisition [Line Items]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	'
	The preliminary purchase price allocation as of the acquisition date is summarized as follows (in thousands):
		26-Nov-12
	Current assets:
	Cash and cash equivalents	$	423
	Accounts receivables and other current assets	72
	Property and equipment	37
	Developed technology	3,200
	In-process research and development	1,300
	Covenants not-to-compete	100
	Other non-current assets	8
	Deferred tax asset	2,391
	Total assets acquired	7,531
	Current liabilities:
	Accounts payable	(56		)
	Accrued expenses	(375		)
	Other long-term debt	(1,100		)
	Deferred tax liability	(1,150		)
	Total liabilities acquired	(2,681		)
	Goodwill	12,409
	Net assets acquired	$	17,259

Financial_Statement_Details_Ta

Financial Statement Details (Tables)	9 Months Ended
	Sep. 30, 2013
Financial Statement Details [Abstract]	'
Available-For-Sale Investments	'
	At September 30, 2013 and December 31, 2012, available-for-sale investments are detailed as follows (in thousands):
	At September 30, 2013
			Amortized				Gross Unrealized				Gross Unrealized				Estimated
			Cost				Gains				Losses				Fair Value
	Short-term:
	Corporate debt securities		$	122,373			$	42			$	4			$	122,411
	U.S. Treasury and agency debt securities		66,377				10				20				66,367
	Short-term available-for-sale investments		$	188,750			$	52			$	24			$	188,778
	Long-term:
	Corporate debt securities		$	34,142			$	20			$	20			$	34,142
	U.S. Treasury and agency debt securities		55,026				42				—				55,068
	Long-term available for sale investments		$	89,168			$	62			$	20			$	89,210
	At December 31, 2012
			Amortized				Gross Unrealized				Gross Unrealized				Estimated
			Cost				Gains				Losses				Fair Value
	Short-term:
	Corporate debt securities		$	121,883			$	52			$	5			$	121,930
	U.S. Treasury and agency debt securities		19,020				10				—				19,030
	Short-term available-for-sale investments		$	140,903			$	62			$	5			$	140,960
	Long-term:
	Corporate debt securities		$	33,384			$	6			$	17			$	33,373
	U.S. Treasury and agency debt securities		11,010				2				—				11,012
	Long-term available for sale investments		$	44,394			$	8			$	17			$	44,385
Available-For-Sale Investments That Are In An Unrealized Loss Position	'
	Available-for-sale investments that are in an unrealized loss position at September 30, 2013 and December 31, 2012 are detailed as follows (in thousands):
			At September 30, 2013
			Estimated				Gross Unrealized
			Fair Value				Losses
	Corporate debt securities		$	37,670			$	24
	U.S. Treasury and agency debt securities		40,992				20
			$	78,662			$	44
			At December 31, 2012
			Estimated				Gross Unrealized
			Fair Value				Losses
	Corporate debt securities		$	46,987			$	22
	U.S. Treasury and agency debt securities		—				—
			$	46,987			$	22
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	'
	The following tables summarize the location and fair values of derivative instruments on our unaudited condensed consolidated balance sheets (in thousands) at September 30, 2013 and December 31, 2012. The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not.
		As of September 30, 2013
		Asset Derivatives						Liability Derivatives
		Balance sheet location		Fair Value				Balance sheet location		Fair Value
	Derivatives Designated as Hedging Instruments
	Foreign exchange forward contracts	Other current assets		$	8			Other current liabilities		$	407
	Foreign exchange forward contracts	Other long-term assets		11				Other long-term liabilities		119
	Total Derivatives Designated as Hedging Instruments			19						526
	Derivatives Not Designated as Hedging Instruments
	Foreign exchange forward contracts	Other current assets		604				Other current liabilities		902
	Total Derivatives Not Designated as Hedging Instruments			604						902
	Total Derivatives			$	623					$	1,428
		As of December 31, 2012
		Asset Derivatives						Liability Derivatives
		Balance sheet location		Fair Value				Balance sheet location		Fair Value
	Derivatives Designated as Hedging Instruments
	Foreign exchange forward contracts	Other current assets		$	—			Other current liabilities		$	—
	Foreign exchange forward contracts	Other long-term assets		—				Other long-term liabilities		—
	Total Derivatives Designated as Hedging Instruments			—						—
	Derivatives Not Designated as Hedging Instruments
	Foreign exchange forward contracts	Other current assets		3,886				Other current liabilities		425
	Total Derivatives Not Designated as Hedging Instruments			3,886						425
	Total Derivatives			$	3,886					$	425
Offsetting Assets and Liabilities	'
	Derivatives not subject to master netting arrangements are not eligible for net presentation.
		As of September 30, 2013
						Gross Amount Not Offset on the Balance Sheet
		Gross Amount of Recognized Assets (Liabilities)				Financial Instruments				Cash Collateral (Received) or Pledged			Net Amount
	Derivative Assets
	Foreign exchange forward contracts	$	623			$	(623	)		—			$	—
	Derivative Liabilities
	Foreign exchange forward contracts	(1,428		)		623				—			(805		)
	Total	$	(805	)		—				—			(805		)
Derivative Instruments, Gain (Loss)	'
	The following table summarizes the effect of our foreign exchange forward contracts on our unaudited Condensed Consolidated Statements of Operations (in thousands).
			Three Months Ended								Nine Months Ended
			September 30,								September 30,
			2013				2012				2013				2012
	Derivatives Designated as Hedging Instruments
	Gain (loss) recognized in other comprehensive income on foreign currency forward contracts (effective portion)		$	(727	)		$	—			$	(719	)		$	—
	Gain (loss) reclassified from accumulated other comprehensive income into cost of revenue (effective portion)		(44		)		—				(44		)		—
	Gain (loss) recognized in income (ineffective portion and amount excluded from effectiveness testing)		43				—				11				—
	Derivatives Not Designated as Hedging Instruments
	Gain (loss) recognized in exchange rate gain (loss), net		$	(996	)		$	(1,243	)		$	4,880			$	517
Financial Assets And Liabilities Measured At Fair Value On A Recurring Basis	'
	Financial assets and liabilities measured at fair value on a recurring basis are summarized below at September 30, 2013 and December 31, 2012 (in thousands):
			Fair Value Measurements at September 30, 2013
			Total				Level 1				Level 2				Level 3
	Assets:
	Current:
	Cash		$	54,198			$	54,198			$	—			$	—
	Money market funds		157,208				157,208				—				—
	Corporate debt securities		122,411				—				122,411				—
	U.S. Treasury and agency debt securities		66,367				66,367				—				—
	Foreign currency forward contracts		612				—				612				—
	Non-current:
	Corporate debt securities		34,142				—				34,142				—
	U.S. Treasury and agency debt securities		55,068				55,068				—				—
	Foreign currency forward contracts		11				—				11				—
	Total assets measured at fair value		$	490,017			$	332,841			$	157,176			$	—
	Liabilities:
	Current:
	Foreign currency forward contracts		$	1,309			$	—			$	1,309			$	—
	Contingent consideration, current portion		2,911				—				—				2,911
	Non-current:
	Foreign currency forward contracts		119				—				119				—
	Other long-term debt		1,207				—				—				$	1,207
	Contingent consideration (1)		29,657				—				—				29,657
	Total liabilities measured at fair value		$	35,203			$	—			$	1,428			$	33,775
	-1	This amount is reflected net of the fair value of the working capital receivable in the amount of $1.1 million at September 30, 2013.
			Fair Value Measurements at December 31, 2012
			Total				Level 1				Level 2				Level 3
	Assets:
	Current:
	Cash		$	41,636			$	41,636			$	—			$	—
	Money market funds		288,999				288,999				—				—
	Corporate debt securities		121,930				—				121,930				—
	U.S. Treasury and agency debt securities		19,030				19,030				—				—
	Foreign currency forward contracts		3,461				—				3,461				—
	Non-current:
	Corporate debt securities		33,373				—				33,373				—
	U.S. Treasury and agency debt securities		11,012				11,012				—				—
	Total assets measured at fair value		$	519,441			$	360,677			$	158,764			$	—
	Liabilities:
	Current:
	Contingent consideration, current portion		$	2,908			$	—			$	—			$	2,908
	Non-current:
	Other long-term debt		1,088				—				$	—			$	1,088
	Contingent consideration (1)		27,323				—				—				27,323
	Total liabilities measured at fair value		$	31,319			$	—			$	—			$	31,319
	-1	This amount is reflected net of the fair value of the working capital receivable in the amount of $907,000 at December 31, 2012.
Inventories	'
	Inventories consist of the following (in thousands):
			September 30, 2013				31-Dec-12
	Finished goods (1)		$	33,302			$	19,002
	Work-in-process		12,022				15,780
	Raw materials		21,643				18,029
			$	66,967			$	52,811
	-1	Finished goods inventory includes consigned inventory of $6.5 million and $5.3 million at September 30, 2013 and December 31, 2012, respectively.
Intangible Assets By Major Class	'
	Intangible assets consisted of the following (in thousands):
			30-Sep-13
	Intangible assets subject to amortization		Cost				Accumulated				Net				Weighted-
							Amortization								Average Life
															(in years) (1)
	Developed technology		$	38,935			$	17,370			$	21,565			10.4
	Licenses		7,422				7,090				332				8
	Customer relationships		4,235				3,934				301				6.1
	Patents and trademarks		11,037				2,521				8,516				13.2
	Covenant not to compete		300				83				217				3
			61,929				30,998				30,931				10.3
	Intangible assets not yet subject to amortization
	In-process research and development		29,700				—				29,700				n/a
			$	91,629			$	30,998			$	60,631
			December 31, 2012
	Intangible assets subject to amortization		Cost				Accumulated				Net				Weighted-
							Amortization								Average Life
															(in years) (1)
	Developed technology		$	27,051			$	17,408			$	9,643			8.8
	Licenses		7,345				6,709				636				10
	Customer relationships		4,177				3,756				421				6
	Patents and trademarks		8,029				2,114				5,915				13.2
	Covenant not to compete		300				8				292				3
			46,902				29,995				16,907				9.4
	Intangible assets not yet subject to amortization
	In-process research and development		33,750				—				33,750				n/a
			$	80,652			$	29,995			$	50,657
	-1	Weighted average life of intangible assets is presented excluding fully amortized assets.
Future Amortization Expense Of Intangible Assets	'
	At September 30, 2013, future amortization expense related to our intangible assets subject to amortization is expected to be as follows (in thousands):
	2013	$	1,068
	2014	4,066
	2015	3,993
	2016	3,725
	2017	3,212
	Thereafter	14,867
		$	30,931
Carrying Values Of The Liability And Equity Components Of The Notes	'
	The carrying values of the liability and equity components of both the 2017 Notes and the 2015 Notes are reflected in our unaudited condensed consolidated balance sheets as follows (in thousands):
			September 30, 2013				December 31, 2012
	Long-term debt:
	2.875% Convertible Senior Notes due 2015:
	Principal amount		$	25,000			$	25,000
	Unamortized discount of liability component		(2,078		)		(2,830		)
	Unamortized debt issuance costs		(234		)		(326		)
	Carrying value of liability component		22,688				21,844
	1.75% Convertible Senior Notes due 2017:
	Principal amount		460,000				460,000
	Unamortized discount of liability component		(76,914		)		(88,536		)
	Unamortized debt issuance costs		(9,563		)		(11,008		)
	Carrying value of liability component		373,523				360,456
	Total long-term debt		$	396,211			$	382,300
	Equity—net carrying value
	2.875% Convertible Senior Notes due 2015		$	452			$	452
	1.75% Convertible Senior Notes due 2017		89,415				89,415
Schedule of Fair Value Of Notes	'
	The fair values of the Notes, which are all Level 2 measurements, are summarized as follows (in thousands):
		September 30, 2013				December 31, 2012
	2.875% Convertible Senior Notes due 2015	$	26,693			$	26,950
	1.75% Convertible Senior Notes due 2017	479,325				462,850
	Total	$	506,018			$	489,800

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Fair Value Of Stock Option On Grant Date Using Weighted-Average Assumptions	'
	The fair value of each stock option is estimated on the date of grant using the Black-Scholes model utilizing the following weighted-average assumptions:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Risk-free interest rate	1.3		%	0.7		%	0.8		%	0.8		%
	Expected life (years)	4.6			4.1			4.2			4.1
	Estimated volatility	41.9		%	46.1		%	39.3		%	47		%
	Expected dividends	None			None			None			None
	Weighted-average grant date fair value	$	7.34		$	10.89		$	7.44		$	10.83
Fair Value Of Stock Option Under The Purchase Plan, Weighted-Average Assumptions	'
	The fair value of each purchase option under the Purchase Plan is estimated at the beginning of each purchase period using the Black-Scholes model utilizing the following weighted-average assumptions:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Risk-free interest rate	0.1		%	0.1		%	0.1		%	0.1		%
	Expected life (years)	0.5			0.5			0.5			0.5
	Estimated volatility	29.6		%	36.8		%	30		%	39.1		%
	Expected dividends	None			None			None			None
	Fair value of purchase right	$	5.53		$	7.07		$	5.21		$	7.32
Table Of Stock-Based Compensation Expense	'
	The following table sets forth stock-based compensation expense included in our unaudited condensed consolidated statements of operations (in thousands):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Cost of revenues	$	196		$	202		$	583		$	515
	Selling, general and administrative	3,592			3,331			10,152			9,606
	Research and development	462			403			1,363			1,307
		$	4,250		$	3,936		$	12,098		$	11,428

Segment_and_Geographic_Informa1

Segment and Geographic Information (Tables)	9 Months Ended
	Sep. 30, 2013
Segment And Geographic Information [Abstract]	'
Schedule Of Revenues By Segment And Product	'
	The following table sets forth our revenues by segment and product (in thousands):
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Medical segment:
	Consoles	$	10,964	$	9,679	$	31,469	$	28,529
	Single-procedure disposables:
	IVUS	46,024		48,574		143,869		153,683
	FM	27,869		24,585		83,345		67,652
	Other	8,809		7,825		25,725		21,286
	Sub-total medical segment	93,666		90,663		284,408		271,150
	Industrial segment	2,143		2,993		5,976		8,239
		$	95,809	$	93,656	$	290,384	$	279,389
Schedule Of Revenues By Geography	'
	The following table sets forth our revenues by geography expressed as dollar amounts (in thousands):
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Revenues (1):
	United States	$	46,673	$	44,083	$	139,076	$	130,152
	Japan	26,368		29,699		82,292		90,025
	Europe, the Middle East and Africa	17,371		13,491		51,512		42,507
	Rest of world	5,397		6,383		17,504		16,705
		$	95,809	$	93,656	$	290,384	$	279,389
	-1	Revenues are attributed to geographies based on the location of the customer, except for shipments to original equipment manufacturers, which are attributed to the country of origin of the equipment distributed.

Summary_Of_Significant_Account3

Summary Of Significant Accounting Policies (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
New Accounting Pronouncements or Change in Accounting Principle [Line Items]	'	'	'	'
Potentially dilutive shares not included in the computation of diluted net income (loss) per share	22.2	2	21.7	2.1
2.875% Convertible Senior Notes Due 2015	'	'	'	'
New Accounting Pronouncements or Change in Accounting Principle [Line Items]	'	'	'	'
Convertible senior notes, interest rate	2.88%	'	2.88%	'
1.75% Convertible Senior Notes Due 2017	'	'	'	'
New Accounting Pronouncements or Change in Accounting Principle [Line Items]	'	'	'	'
Convertible senior notes, interest rate	1.75%	'	1.75%	'
Options Held [Member] | 2.875% Convertible Senior Notes Due 2015	'	'	'	'
New Accounting Pronouncements or Change in Accounting Principle [Line Items]	'	'	'	'
Initial effective conversion price	29.64	'	29.64	'
Options Held [Member] | 1.75% Convertible Senior Notes Due 2017	'	'	'	'
New Accounting Pronouncements or Change in Accounting Principle [Line Items]	'	'	'	'
Initial effective conversion price	32.83	'	32.83	'
Warrant [Member] | 2.875% Convertible Senior Notes Due 2015	'	'	'	'
New Accounting Pronouncements or Change in Accounting Principle [Line Items]	'	'	'	'
Investment warrants exercise price	'	'	34.875	'
Warrant [Member] | 1.75% Convertible Senior Notes Due 2017	'	'	'	'
New Accounting Pronouncements or Change in Accounting Principle [Line Items]	'	'	'	'
Investment warrants exercise price	'	'	37.59	'

Summary_Of_Significant_Account4

Summary Of Significant Accounting Policies (Schedule Of Basic And Diluted Net Income (Loss) Per Common Share Calculations) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]	'	'	'	'
Net (loss) income	($8,456)	$1,975	($14,005)	$5,545
Weighted average common shares outstanding for basic	54,652	53,659	54,466	53,309
Weighted average common shares outstanding for diluted	54,652	55,265	54,466	55,097
Net (loss) income per share:	'	'	'	'
Basic (dollars per share)	($0.15)	$0.04	($0.26)	$0.10
Diluted (dollars per share)	($0.15)	$0.04	($0.26)	$0.10
Stock Options [Member]	'	'	'	'
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]	'	'	'	'
Dilutive potential common stock outstanding	0	1,376	0	1,481
Restricted Stock Units (RSUs) [Member]	'	'	'	'
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]	'	'	'	'
Dilutive potential common stock outstanding	0	222	0	300
Employee Stock Purchase Plan [Member]	'	'	'	'
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]	'	'	'	'
Dilutive potential common stock outstanding	0	8	0	7

Acquisitions_Acquisitions_Pion

Acquisitions Acquisitions (Pioneer Acquisition - Narrative) (Details) (Pioneer Plus Re-entry Catheter [Member], USD $)	0 Months Ended
In Thousands, unless otherwise specified	Aug. 30, 2013
Pioneer Plus Re-entry Catheter [Member]	'
Business Acquisition [Line Items]	'
Total purchase price	$15,000

Acquisitions_Crux_Acquisition_

Acquisitions (Crux Acquisition - Narrative) (Details) (USD $)

3 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

6 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Dec. 12, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 12, 2012

Dec. 12, 2012

Sep. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Various Sales Milestones [Member]

Various Sales Milestones [Member]

Various Sales Milestones [Member]

Various Sales Milestones [Member]

Various Sales Milestones [Member]

Minimum [Member]

Maximum [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquisition-related items

$1,253,000

$0

$3,742,000

$0

'

'

'

'

'

'

'

'

'

'

'

Goodwill

53,082,000

'

53,082,000

'

51,577,000

'

38,182,000

38,182,000

'

'

'

'

'

'

'

Business combination, provisional information, initial accounting incomplete, adjustment, consideration transferred

'

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

Total up-front payments

'

'

'

'

'

39,100,000

'

'

'

'

'

'

'

'

'

Business acquisition, percentage of voting interests acquired

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

Payments to acquire businesses, gross, escrow amount

'

'

'

'

'

3,900,000

'

'

'

'

'

'

'

'

'

Business combination, consideration transferred, estimated working capital fair value adjustment settlement

'

'

'

'

'

1,200,000

1,400,000

1,400,000

'

'

'

'

'

'

'

Estimated fair value of receivable for working capital adjustment

'

'

'

'

'

-900,000

1,100,000

'

'

'

'

'

'

'

'

Business combination, contingent consideration arrangements, range of outcomes, estimated amount

'

'

'

'

'

'

'

'

'

3,000,000

46,600,000

'

'

'

'

Estimated fair value of contingent consideration

'

'

'

'

'

30,900,000

'

'

2,900,000

'

28,000,000

'

'

'

'

Fair Value Assumptions, Probability of Success

'

'

'

'

'

'

'

'

99.00%

'

'

'

'

'

'

Business combination, contingent consideration arrangements, change in amount of contingent consideration, liability

'

'

'

'

'

'

881,000

2,500,000

'

'

'

'

'

'

'

Fair value inputs, discount rate

'

'

'

'

'

'

'

'

5.00%

'

'

14.00%

'

'

'

Business combination, contingent consideration arrangements, range of outcomes, value, low

'

'

'

'

'

'

'

'

'

'

'

'

32,800,000

'

'

Business combination, contingent consideration arrangements, range of outcomes, value, high

'

'

'

'

'

'

'

'

'

'

'

'

70,100,000

'

'

Fair value inputs, commercial sales

'

'

'

'

'

'

'

'

'

'

'

'

'

118,600,000

304,200,000

In-process research and development

'

'

'

'

'

$28,400,000

'

'

'

'

'

'

'

'

'

Fair value assumption, weighted average cost of capital

'

'

'

'

'

'

'

14.00%

'

'

'

'

'

'

'

Acquisitions_Acquisitions_Crux

Acquisitions Acquisitions (Crux Acquisition - Contingent Consideration Rollforward) (Details) (Crux Acquisition [Member], USD $)	3 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013
Business Combination, Contingent Consideration, Liability [Roll Forward]	'	'
Business Combination, Contingent Consideration, Liability	$31,687	$30,231
Business combination, contingent consideration arrangements, change in amount of contingent consideration, liability	881	2,500
Business Combination, Contingent Consideration Arrangements, Amount of Contingent Consideration Settled, Liability	0	0
Business Combination, Contingent Consideration, Liability	32,568	32,568
Operating Expense [Member]	'	'
Business Combination, Contingent Consideration, Liability [Roll Forward]	'	'
Business combination, contingent consideration arrangements, change in amount of contingent consideration, liability	$881	$2,337

Acquisitions_Crux_Acquisition_1

Acquisitions (Crux Acquisition - Reconciliation of Upfront Payments) (Details) (Crux Acquisition [Member], USD $)	0 Months Ended	3 Months Ended
In Thousands, unless otherwise specified	Dec. 12, 2012	Sep. 30, 2013
Crux Acquisition [Member]	'	'
Business Acquisition [Line Items]	'	'
Base payment per agreement	$36,000	'
Reimbursement of transaction expenses incurred by Crux	3,100	'
Total up-front payments	39,100	'
Estimated fair value of receivable for working capital adjustment	-900	1,100
Estimated fair value of contingent consideration	30,900	'
Total purchase price	$68,900	'

Acquisitions_Crux_Acquisition_2

Acquisitions (Crux Acquisition - Purchase Price Allocation as of Acquisition Date) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 12, 2012
In Thousands, unless otherwise specified			Crux Acquisition [Member]	Crux Acquisition [Member]
Current assets:	'	'	'	'
Cash and cash equivalents	'	'	'	$1,474
Other current assets	'	'	'	253
Property and equipment	'	'	'	39
In-process research and development	'	'	'	28,400
Covenant-not-to-compete	'	'	'	200
Deferred tax asset	'	'	'	11,281
Total assets acquired	'	'	'	41,647
Current liabilities:	'	'	'	'
Accounts payable	'	'	'	-223
Accrued expenses	'	'	'	-302
Other long term payable	'	'	'	-97
Deferred tax liability	'	'	'	-10,307
Total liabilities assumed	'	'	'	-10,929
Goodwill	53,082	51,577	38,182	'
Net assets acquired	'	'	'	$68,900

Acquisitions_Crux_Acquisition_3

Acquisitions (Crux Acquisition - Pro Forma Information Date) (Details) (Crux Acquisition [Member], USD $)	3 Months Ended	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2012	Sep. 30, 2012
Crux Acquisition [Member]	'	'
Business Acquisition [Line Items]	'	'
Revenues	$93,656	$279,389
Net loss	$471	$1,333
Net loss per share, basic and diluted:	'	'
Basic (dollars per share)	$0.01	$0.03
Diluted (dollars per share)	$0.01	$0.02
Shares used in computing basic and diluted net loss per share:	'	'
Basic (shares)	53,659	53,309
Diluted (shares)	55,265	55,097

Acquisitions_SyncRx_Acquisitio

Acquisitions (Sync-Rx Acquisition - Narrative) (Details) (USD $)

3 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Nov. 26, 2012

Nov. 26, 2012

Nov. 26, 2012

Nov. 26, 2012

Dec. 12, 2012

Sep. 30, 2013

Sep. 30, 2013

Aug. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Nov. 26, 2012

Nov. 26, 2012

Nov. 26, 2012

Nov. 26, 2012

Synch-Rx Acquisition [Member]

Synch-Rx Acquisition [Member]

Synch-Rx Acquisition [Member]

Synch-Rx Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Pioneer Plus Re-entry Catheter [Member]

Pioneer Plus Re-entry Catheter [Member]

Pioneer Plus Re-entry Catheter [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Government Grant to Develop Underlying Technology [Member]

Developed technology

In-process research and development

Synch-Rx Acquisition [Member]

Synch-Rx Acquisition [Member]

Synch-Rx Acquisition [Member]

Synch-Rx Acquisition [Member]

Government Grant to Develop Underlying Technology [Member]

Government Grant to Develop Underlying Technology [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Developed technology

'

'

'

'

'

$3,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Total purchase price

'

'

'

'

'

17,300,000

'

'

'

68,900,000

'

'

15,000,000

'

'

'

'

'

'

Payments to acquire businesses, gross, escrow amount

'

'

'

'

'

3,300,000

'

'

'

3,900,000

'

'

'

'

'

'

'

'

'

Time frame for claims (in months)

'

'

'

'

'

'18 months

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill

53,082,000

'

53,082,000

'

51,577,000

12,409,000

'

'

'

'

38,182,000

38,182,000

'

'

'

'

'

'

'

Acquisition-related items

1,253,000

0

3,742,000

0

'

'

'

'

'

'

'

'

'

358,000

810,000

'

'

'

'

Business combination, contingent consideration arrangements, change in amount of contingent consideration, liability

'

'

'

'

'

'

'

'

'

'

881,000

2,500,000

'

'

'

'

'

'

'

Estimated fair value of contingent consideration

'

'

'

'

'

'

1,100,000

'

'

30,900,000

'

'

'

'

'

'

'

'

'

Fair value inputs, discount rate

'

'

'

'

'

8.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Business combination, estimated commercial sales

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

256,100,000

'

298,300,000

'

Business acqusition, development grant, liability, repayment period (in years)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'16 years

Business combination, contingent consideration arrangements, range of outcomes, estimated amount

'

'

'

'

'

'

$1,900,000

'

'

'

'

'

'

'

'

'

'

'

'

Finite-lived intangible assets, estimated useful life intangible (in years)

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount rate, after-tax cash flows present value

'

'

'

'

'

'

'

19.00%

20.00%

'

'

'

'

'

'

'

'

'

'

Acquisitions_SyncRx_Acquisitio1

Acquisitions (Sync-Rx Acquisition - Purchase Price Allocation as of Acquisiton Date) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Nov. 26, 2012
In Thousands, unless otherwise specified			Synch-Rx Acquisition [Member]
Current assets:	'	'	'
Cash and cash equivalents	'	'	$423
Accounts receivables and other current assets	'	'	72
Property and equipment	'	'	37
Developed technology	'	'	3,200
In-process research and development	'	'	1,300
Covenant-not-to-compete	'	'	100
Other non-current assets	'	'	8
Deferred tax asset	'	'	2,391
Total assets acquired	'	'	7,531
Current liabilities:	'	'	'
Accounts payable	'	'	-56
Accrued expenses	'	'	-375
Other long-term debt	'	'	-1,100
Deferred tax liability	'	'	-1,150
Total liabilities assumed	'	'	-2,681
Goodwill	53,082	51,577	12,409
Net assets acquired	'	'	$17,259

Financial_Statement_Details_Na

Financial Statement Details (Narrative) (Details) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

15 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

1 Months Ended

Share data in Thousands, except Per Share data, unless otherwise specified

Jun. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2014

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 10, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 10, 2012

Sep. 30, 2013

Jun. 30, 2013

Forecast

In-process research and development

1.75% Convertible Senior Notes Due 2017

2.875% Convertible Senior Notes Due 2015

2.875% Convertible Senior Notes Due 2015

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Options Held [Member]

Options Held [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Call Options [Member]

Call Options [Member]

Call Options [Member]

Cost of Sales [Member]

Cash Flow Hedging [Member]

Cash Flow Hedging [Member]

1.75% Convertible Senior Notes Due 2017

2.875% Convertible Senior Notes Due 2015

2.875% Convertible Senior Notes Due 2015

1.75% Convertible Senior Notes Due 2017

2.875% Convertible Senior Notes Due 2015

1.75% Convertible Senior Notes Due 2017

2.875% Convertible Senior Notes Due 2015

2.875% Convertible Senior Notes Due 2015

Derivatives, Fair Value [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maturity period for investments, months

'

'22 months

'

'22 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum remaining maturity of foreign currency derivatives

'

'

'

'16 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notional amount of foreign currency forward contracts

'

'

'

'

'

'

'

'

'

'

$95,200,000

$64,400,000

$41,300,000

$0

'

'

'

'

'

'

'

'

'

'

'

Accumulated other comprehensive income (loss), cumulative changes in net gain (loss) from cash flow hedges, effect net of tax

'

414,000

'

414,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of foreign currency forward contracts included in prepaid and other current assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

612,000

3,461,000

'

'

'

'

Right to purchase common stock, number of shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14,000

3,900

850

'

'

'

'

14,000

3,900

850

'

Purchase price of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

32.8286

'

29.64

'

Investment warrants exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$37.59

'

$34.88

'

'

'

'

'

'

'

'

Employee severance, minimum retention period

'60 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Asset impairment related to restructuring

'

'

'

4,616,000

0

4,100,000

4,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, repurchase amount

'

'

'

'

'

'

'

'

90,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate principal amount

'

'

'

'

'

'

'

460,000,000

'

115,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible senior notes, interest rate

'

'

'

'

'

'

'

1.75%

'

2.88%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring charges

'

4,616,000

0

4,874,000

0

14,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

258,000

Severance costs

'

'

'

'

'

2,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other restructuring costs

'

'

'

'

'

7,873,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring charges, estimated future amount

'

'

'

'

'

10,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repayments of long-term debt

'

'

'

'

'

'

'

'

$90,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial effective conversion price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$32.83

$29.64

'

'

'

'

'

'

Financial_Statement_Details_Av

Financial Statement Details (Available-For-Sale Investments) (Details) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Gross Unrealized Losses	$44	$22
Available-for-sale Securities, Fair Value Disclosure	78,662	46,987
Corporate debt securities	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Gross Unrealized Losses	24	22
Available-for-sale Securities, Fair Value Disclosure	37,670	46,987
U.S. Treasury and agency debt securities	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Gross Unrealized Losses	20	0
Available-for-sale Securities, Fair Value Disclosure	40,992	0
Short-term	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Amortized Cost	188,750	140,903
Available-for-sale securities, Gross Unrealized Gains	52	62
Available-for-sale securities, Gross Unrealized Losses	24	5
Available-for-sale Securities, Fair Value Disclosure	188,778	140,960
Short-term | Corporate debt securities	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Amortized Cost	122,373	121,883
Available-for-sale securities, Gross Unrealized Gains	42	52
Available-for-sale securities, Gross Unrealized Losses	4	5
Available-for-sale Securities, Fair Value Disclosure	122,411	121,930
Short-term | U.S. Treasury and agency debt securities	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Amortized Cost	66,377	19,020
Available-for-sale securities, Gross Unrealized Gains	10	10
Available-for-sale securities, Gross Unrealized Losses	20	0
Available-for-sale Securities, Fair Value Disclosure	66,367	19,030
Long-term	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Amortized Cost	89,168	44,394
Available-for-sale securities, Gross Unrealized Gains	62	8
Available-for-sale securities, Gross Unrealized Losses	20	17
Available-for-sale Securities, Fair Value Disclosure	89,210	44,385
Long-term | Corporate debt securities	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Amortized Cost	34,142	33,384
Available-for-sale securities, Gross Unrealized Gains	20	6
Available-for-sale securities, Gross Unrealized Losses	20	17
Available-for-sale Securities, Fair Value Disclosure	34,142	33,373
Long-term | U.S. Treasury and agency debt securities	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Amortized Cost	55,026	11,010
Available-for-sale securities, Gross Unrealized Gains	42	2
Available-for-sale securities, Gross Unrealized Losses	0	0
Available-for-sale Securities, Fair Value Disclosure	$55,068	$11,012

Financial_Statement_Details_Av1

Financial Statement Details (Available-For-Sale Investments That Are In An Unrealized Loss Position) (Details) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Estimated Fair Value	$78,662	$46,987
Available-for-sale Securities, Gross Unrealized Losses	44	22
Corporate debt securities	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Estimated Fair Value	37,670	46,987
Available-for-sale Securities, Gross Unrealized Losses	24	22
U.S. Treasury and agency debt securities	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Estimated Fair Value	40,992	0
Available-for-sale Securities, Gross Unrealized Losses	$20	$0

Financial_Statement_Details_Fi

Financial Statement Details Financial Statement Details (Foreign Currency Forward Contract) (Details) (Foreign Exchange Forward [Member], USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Derivatives, Fair Value [Line Items]	'	'
Derivative Asset, Notional Amount	$623	$3,886
Derivative Liability, Notional Amount	1,428	425
Designated as Hedging Instrument [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative Asset, Notional Amount	19	0
Derivative Liability, Notional Amount	526	0
Not Designated as Hedging Instrument [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative Asset, Notional Amount	604	3,886
Derivative Liability, Notional Amount	902	425
Other Current Assets [Member] | Designated as Hedging Instrument [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative Asset, Notional Amount	8	0
Other Current Assets [Member] | Not Designated as Hedging Instrument [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative Asset, Notional Amount	604	3,886
Other Current Liabilities [Member] | Designated as Hedging Instrument [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative Liability, Notional Amount	407	0
Other Current Liabilities [Member] | Not Designated as Hedging Instrument [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative Liability, Notional Amount	902	425
Other Noncurrent Assets [Member] | Designated as Hedging Instrument [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative Asset, Notional Amount	11	0
Other Noncurrent Liabilities [Member] | Designated as Hedging Instrument [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative Liability, Notional Amount	$119	$0

Financial_Statement_Details_Fi1

Financial Statement Details Financial Statement Details (Effect Of Foreign Exchange Forward Contracts On Consolidated Statements Of Income) (Details) (Foreign Exchange Forward [Member], USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Designated as Hedging Instrument [Member]	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	($727)	$0	($719)	$0
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	-44	0	-44	0
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	43	0	11	0
Not Designated as Hedging Instrument [Member]	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Derivative, Gain (Loss) on Derivative, Net	($996)	($1,243)	$4,880	$517

Financial_Statement_Details_Fi2

Financial Statement Details (Financial Assets And Liabilities Measured At Fair Value On A Recurring Basis) (Details) (USD $)	Sep. 30, 2013		Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	$188,778,000		$140,960,000
Available-for-sale Securities, Noncurrent	89,210,000		44,385,000
Assets, fair value disclosure	490,017,000		519,441,000
Total long-term liabilities measured at fair value	35,203,000		31,319,000
Fair value of working capital receivable	-1,100,000		-907,000
Level 1 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Assets, fair value disclosure	332,841,000		360,677,000
Total long-term liabilities measured at fair value	0		0
Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Assets, fair value disclosure	157,176,000		158,764,000
Total long-term liabilities measured at fair value	1,428,000		0
Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Assets, fair value disclosure	0		0
Total long-term liabilities measured at fair value	33,775,000		31,319,000
Cash [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash and cash equivalents	54,198,000		41,636,000
Cash [Member] | Level 1 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash and cash equivalents	54,198,000		41,636,000
Cash [Member] | Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash and cash equivalents	0		0
Cash [Member] | Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash and cash equivalents	0		0
Money Market Funds [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash and cash equivalents	157,208,000		288,999,000
Money Market Funds [Member] | Level 1 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash and cash equivalents	157,208,000		288,999,000
Money Market Funds [Member] | Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash and cash equivalents	0		0
Money Market Funds [Member] | Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash and cash equivalents	0		0
Corporate debt securities	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	122,411,000		121,930,000
Available-for-sale Securities, Noncurrent	34,142,000		33,373,000
Corporate debt securities | Level 1 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	0		0
Available-for-sale Securities, Noncurrent	0		0
Corporate debt securities | Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	122,411,000		121,930,000
Available-for-sale Securities, Noncurrent	34,142,000		33,373,000
Corporate debt securities | Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	0		0
Available-for-sale Securities, Noncurrent	0		0
U.S. Treasury And Agency Short Term Debt Securities [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	66,367,000		19,030,000
U.S. Treasury And Agency Short Term Debt Securities [Member] | Level 1 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	66,367,000		19,030,000
U.S. Treasury And Agency Short Term Debt Securities [Member] | Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	0		0
U.S. Treasury And Agency Short Term Debt Securities [Member] | Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	0		0
Foreign Currency Forward Contracts [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Foreign currency forward contracts	612,000		3,461,000
Foreign currency forward contracts	11,000		'
Foreign currency forward contracts	1,309,000		'
Foreign currency forward contracts	119,000		'
Other long-term debt	1,207,000		'
Foreign Currency Forward Contracts [Member] | Level 1 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Foreign currency forward contracts	0		0
Foreign currency forward contracts	0		'
Foreign currency forward contracts	0		'
Foreign currency forward contracts	0		'
Other long-term debt	0		'
Foreign Currency Forward Contracts [Member] | Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Foreign currency forward contracts	612,000		3,461,000
Foreign currency forward contracts	11,000		'
Foreign currency forward contracts	1,309,000		'
Foreign currency forward contracts	119,000		'
Other long-term debt	0		'
Foreign Currency Forward Contracts [Member] | Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Foreign currency forward contracts	0		0
Foreign currency forward contracts	0		'
Foreign currency forward contracts	0		'
Foreign currency forward contracts	0		'
Other long-term debt	1,207,000		'
US Government Agencies Debt Securities [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Noncurrent	55,068,000		11,012,000
US Government Agencies Debt Securities [Member] | Level 1 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Noncurrent	55,068,000		11,012,000
US Government Agencies Debt Securities [Member] | Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Noncurrent	0		0
US Government Agencies Debt Securities [Member] | Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Noncurrent	0		0
Commitments [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Commitments, current, fair value	2,911,000		'
Contigent considerations	29,657,000	[1]	'
Commitments [Member] | Level 1 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Commitments, current, fair value	0		0
Other long-term debt	'		0
Contigent considerations	0	[1]	0	[2]
Commitments [Member] | Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Commitments, current, fair value	0		'
Other long-term debt	'		0
Contigent considerations	0	[1]	0	[2]
Commitments [Member] | Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Commitments, current, fair value	2,911,000		2,908,000
Other long-term debt	'		1,088,000
Contigent considerations	$29,657,000	[1]	$27,323,000	[2]
[1]	This amount is reflected net of the fair value of the working capital receivable in the amount of $1.1 million at September 30, 2013.
[2]	This amount is reflected net of the fair value of the working capital receivable in the amount of $907,000 at December 31, 2012.

Financial_Statement_Details_Fi3

Financial Statement Details Financial Statement Details (Offsetting Assets and Liabilities) (Details) (Foreign Exchange Forward [Member], USD $)	Sep. 30, 2013
In Thousands, unless otherwise specified
Foreign Exchange Forward [Member]	'
Offsetting Liabilities [Line Items]	'
Gross Amount of Recognized Liabilites	($1,428)
Financial Instruments	623
Cash Collateral (Received) or Pledged	0
Net Amount	-805
Offsetting Assets [Line Items]	'
Gross Amount of Recognized Assets	623
Financial Instruments	-623
Cash Collateral (Received) or Pledged	0
Net Amount	0
Gross Amount of Recognized Assets (Liabilities)	-805
Financial Instruments	0
Cash Collateral (Received) or Pledged	0
Net Amount	($805)

Financial_Statement_Details_In

Financial Statement Details (Inventories) (Details) (USD $)	Sep. 30, 2013		Dec. 31, 2012
Financial Statement Details [Abstract]	'		'
Finished goods	$33,302,000	[1]	$19,002,000	[1]
Work-in-process	12,022,000		15,780,000
Raw materials	21,643,000		18,029,000
Inventories	66,967,000		52,811,000
Consigned inventory	$6,500,000		$5,300,000
[1]	Finished goods inventory includes consigned inventory of $6.5 million and $5.3 million at September 30, 2013 and December 31, 2012, respectively.

Financial_Statement_Details_In1

Financial Statement Details (Intangible Assets By Major Class) (Details) (USD $)	3 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013		Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'		'
Cost	$91,629		$80,652
Accumulated Amortization	30,998		29,995
Net	60,631		50,657
Developed technology	'		'
Finite-Lived Intangible Assets [Line Items]	'		'
Cost	38,935		27,051
Accumulated Amortization	17,370		17,408
Net	21,565		9,643
Weighted average useful lives of intangible assets (in years)	'10 years 5 months	[1]	'8 years 9 months 18 days	[1]
Licenses	'		'
Finite-Lived Intangible Assets [Line Items]	'		'
Cost	7,422		7,345
Accumulated Amortization	7,090		6,709
Net	332		636
Weighted average useful lives of intangible assets (in years)	'8 years	[1]	'10 years	[1]
Customer relationships	'		'
Finite-Lived Intangible Assets [Line Items]	'		'
Cost	4,235		4,177
Accumulated Amortization	3,934		3,756
Net	301		421
Weighted average useful lives of intangible assets (in years)	'6 years 1 month	[1]	'6 years	[1]
Patents and trademarks	'		'
Finite-Lived Intangible Assets [Line Items]	'		'
Cost	11,037		8,029
Accumulated Amortization	2,521		2,114
Net	8,516		5,915
Weighted average useful lives of intangible assets (in years)	'13 years 2 months 16 days	[1]	'13 years 2 months 12 days	[1]
Covenant not to compete	'		'
Finite-Lived Intangible Assets [Line Items]	'		'
Cost	300		300
Accumulated Amortization	83		8
Net	217		292
Weighted average useful lives of intangible assets (in years)	'3 years	[1]	'3 years	[1]
Intangible assets subject to amortization	'		'
Finite-Lived Intangible Assets [Line Items]	'		'
Cost	61,929		46,902
Accumulated Amortization	30,998		29,995
Net	30,931		16,907
Weighted average useful lives of intangible assets (in years)	'10 years 3 months	[1]	'9 years 4 months 24 days	[1]
In-process research and development	'		'
Finite-Lived Intangible Assets [Line Items]	'		'
Cost	29,700		33,750
Accumulated Amortization	0		0
Net	$29,700		$33,750
[1]	Weighted average life of intangible assets is presented excluding fully amortized assets.

Financial_Statement_Details_Fu

Financial Statement Details (Future Amortization Expense Of Intangible Assets) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Net	$60,631	$50,657
Intangible assets subject to amortization	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
2013	1,068	'
2014	4,066	'
2015	3,993	'
2016	3,725	'
2017	3,212	'
Thereafter	14,867	'
Net	$30,931	$16,907

Financial_Statement_Details_Ca

Financial Statement Details (Carrying Values Of The Liability And Equity Components Of The Notes) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
Carrying value of liability component	$396,211	$382,300
2.875% Convertible Senior Notes Due 2015	'	'
Debt Instrument [Line Items]	'	'
Principal amount	25,000	25,000
Unamortized discount of liability component	-2,078	-2,830
Unamortized debt issuance costs	-234	-326
Carrying value of liability component	22,688	21,844
Equity - net carrying value	452	452
1.75% Convertible Senior Notes Due 2017	'	'
Debt Instrument [Line Items]	'	'
Principal amount	460,000	460,000
Unamortized discount of liability component	-76,914	-88,536
Unamortized debt issuance costs	-9,563	-11,008
Carrying value of liability component	373,523	360,456
Equity - net carrying value	$89,415	$89,415

Financial_Statement_Details_Li

Financial Statement Details (Liability and Equity Component Of Notes Measured At Fair Value) (Details) (Level 2 [Member], USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Convertible Senior Notes	$506,018	$489,800
2.875% Convertible Senior Notes Due 2015	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Convertible Senior Notes	26,693	26,950
1.75% Convertible Senior Notes Due 2017	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Convertible Senior Notes	$479,325	$462,850

Commitments_and_Contingencies_

Commitments and Contingencies (Narrative) (Details)

0 Months Ended

1 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

Apr. 07, 2011

Apr. 07, 2010

Nov. 30, 2012

Sep. 30, 2013

Jan. 28, 2011

Oct. 31, 2007

Dec. 12, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 12, 2012

Dec. 12, 2012

USD ($)

USD ($)

EUR (€)

USD ($)

USD ($)

USD ($)

Crux Acquisition [Member]

Minimum [Member]

Maximum [Member]

USDA or FDA, Clearance of 501(k) Aplication Submission [Member]

USDA or FDA, Clearance of 501(k) Aplication Submission [Member]

Various Sales Milestones [Member]

USD ($)

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

USD ($)

USD ($)

USD ($)

Loss Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Stipulated amount that would be treated as the jury's verdict against the defendants in the damages trial

'

$200,000

'

'

'

'

'

'

'

'

'

'

Additional damages awarded

'

'

'

'

400,000

'

'

'

'

'

'

'

Loss contingency, damages awarded, value

600,000

'

'

'

'

'

'

'

'

'

'

'

Attorney's fees

4,500,000

'

'

'

'

'

'

'

'

'

'

'

Settlement payment obligation to third party

'

'

'

5,400,000

'

'

'

'

'

'

'

'

Alleged payment to influence outcome of clinical trial

'

'

5,000

'

'

'

'

'

'

'

'

'

Purchase commitments

'

'

'

29,700,000

'

'

'

'

'

'

'

'

Purchase commitments that require payments in 12 months

'

'

'

23,300,000

'

'

'

'

'

'

'

'

Commitments will require payments (in months)

'

'

'

'12 months

'

'

'

'

'

'

'

'

Purchase commitments that require payments in 3 months

'

'

'

16,400,000

'

'

'

'

'

'

'

'

Agreement to fund clinical study activities

'

'

'

2,100,000

'

4,600,000

'

'

'

'

'

'

Contractual payments due (in years)

'

'

'

'

'

'

'

'1 year

'3 years

'

'

'

Business combination, contingent consideration arrangements, range of outcomes, estimated amount

'

'

'

'

'

'

'

'

'

'

3,000,000

46,600,000

Estimated fair value of contingent consideration

'

'

'

'

'

'

$30,900,000

'

'

$2,900,000

'

$28,000,000

Number of months needed replace sole source suppliers

'

'

'

'

'

'

'

'6 months

'24 months

'

'

'

Stockholders_Equity_Narrative_

Stockholders' Equity (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	15-May-13	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Common stock, shares authorized	250,000,000	'	250,000,000	'	'	250,000,000
Increase in common stock shares issued in equity compensation plan	'	'	'	'	5,360,000	'
Non-cash stock compensation expense	$4,250	$3,936	$12,098	$11,428	'	'
Amended Plan [Member]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Common stock, shares authorized	21,572,558	'	21,572,558	'	'	'
Common stock issued in equity compensation plan	6,724,993	'	6,724,993	'	'	'
Purchase Plan [Member]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Common stock issued in equity compensation plan	55,911	'	55,911	'	'	'

Stockholders_Equity_Fair_Value

Stockholders' Equity (Fair Value Of Stock Option On Grant Date Using Weighted-Average Assumptions) (Details) (Stock Option [Member], USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Stock Option [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Risk-free interest rate	1.30%	0.70%	0.80%	0.80%
Expected life (years)	'4 years 7 months 6 days	'4 years 1 month 6 days	'4 years 2 months 12 days	'4 years 1 month 6 days
Estimated volatility	41.90%	46.10%	39.30%	47.00%
Weighted-average grant date fair value	$7.34	$10.89	$7.44	$10.83

Stockholders_Equity_Fair_Value1

Stockholders' Equity (Fair Value Of Stock Option Under The Purchase Plan Weighted-Average Assumptions) (Details) (Purchase Option Under Purchase Plan [Member], USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Purchase Option Under Purchase Plan [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Risk-free interest rate	0.10%	0.10%	0.10%	0.10%
Expected life (years)	'6 months	'6 months	'6 months	'6 months
Estimated volatility	29.60%	36.80%	30.00%	39.10%
Fair value of purchase right	$5.53	$7.07	$5.21	$7.32

Stockholders_Equity_Table_Of_S

Stockholders' Equity (Table Of Stock-Based Compensation Expense) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Non-cash stock compensation expense	$4,250	$3,936	$12,098	$11,428
Cost of revenues	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Non-cash stock compensation expense	196	202	583	515
Selling, general and administrative	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Non-cash stock compensation expense	3,592	3,331	10,152	9,606
Research and development	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Non-cash stock compensation expense	$462	$403	$1,363	$1,307

Segment_and_Geographic_Informa2

Segment and Geographic Information (Narrative) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Segment Reporting Information [Line Items]	'	'
Goodwill	$53,082	$51,577
United States [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Percentage of long-lived assets excluding financial assets	50.00%	42.00%
Costa Rica [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Percentage of long-lived assets excluding financial assets	38.00%	42.00%
Japan [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Percentage of long-lived assets excluding financial assets	8.00%	12.00%
Rest Of World [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Percentage of long-lived assets excluding financial assets	4.00%	4.00%

Segment_and_Geographic_Informa3

Segment and Geographic Information (Schedule Of Revenues By Segment And Product) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Segment Reporting Information [Line Items]	'	'	'	'
Revenues	$95,809	$93,656	$290,384	$279,389
Medical segment	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenues	93,666	90,663	284,408	271,150
Industrial segment	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenues	2,143	2,993	5,976	8,239
Consoles [Member] | Medical segment	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenues	10,964	9,679	31,469	28,529
IVUS [Member] | Medical segment	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenues	46,024	48,574	143,869	153,683
FM [Member] | Medical segment	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenues	27,869	24,585	83,345	67,652
Other [Member] | Medical segment	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenues	$8,809	$7,825	$25,725	$21,286

Segment_and_Geographic_Informa4

Segment and Geographic Information (Schedule Of Revenues By Geography) (Details) (USD $)	3 Months Ended				9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013		Sep. 30, 2012		Sep. 30, 2013	Sep. 30, 2012
Segment Reporting Information [Line Items]	'		'		'	'
Revenues	$95,809		$93,656		$290,384	$279,389
United States [Member]	'		'		'	'
Segment Reporting Information [Line Items]	'		'		'	'
Revenues	46,673	[1]	44,083	[1]	139,076	130,152
Japan [Member]	'		'		'	'
Segment Reporting Information [Line Items]	'		'		'	'
Revenues	26,368	[1]	29,699	[1]	82,292	90,025
Europe, The Middle East And Africa [Member]	'		'		'	'
Segment Reporting Information [Line Items]	'		'		'	'
Revenues	17,371	[1]	13,491	[1]	51,512	42,507
Rest Of World [Member]	'		'		'	'
Segment Reporting Information [Line Items]	'		'		'	'
Revenues	$5,397	[1]	$6,383	[1]	$17,504	$16,705
[1]	Revenues are attributed to geographies based on the location of the customer, except for shipments to original equipment manufacturers, which are attributed to the country of origin of the equipment distributed.

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Tax Disclosure [Abstract]	'	'	'	'
Income tax (credit) expense	($4,392)	$2,130	($10,156)	$4,295
Effective income tax rate	'	'	42.00%	43.60%
Effective income tax rate, continuing operations excluding research and development tax credit	'	'	38.00%	'
U.S. federal statutory income tax rate	'	'	35.00%	'